[{"text": "PREMIUM Climb Bio Signs Deal With Beijing Mabworks Biotech to Develop Antibody for IgA Nephropathy MT Newswires Thu, Jan 9, 2025, 8:27 PM 1 min read Climb Bio (CLYM) said Thursday it has signed an exclusive licensing deal with Beijing Mabworks Biote PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLYM", "date": "2025-01-09T20:27:07", "sentiment": {"score": 0.16911144647747278, "confidence": 0.17817145586013794, "probabilities": {"positive": 0.17817145586013794, "negative": 0.009060009382665157, "neutral": 0.8127685785293579}}, "embedding": [-0.26989415287971497, -0.057116322219371796, 0.19613339006900787, -0.13744989037513733, 0.0031284743454307318, -0.07838316261768341, 0.04758354276418686, 0.1244194433093071, 0.010869134217500687, 0.039121631532907486, -0.04606828838586807, -0.026575472205877304, -0.0032457313500344753, 0.25316062569618225, 0.12668375670909882, 0.13773733377456665, -0.04170835390686989, -0.021485211327672005, 0.14198623597621918, -0.09924077987670898, -0.060539111495018005, -0.029361795634031296, 0.021617595106363297, 0.09803831577301025, -0.08893204480409622, -0.12773187458515167, -0.15469560027122498, 0.12036184221506119, 0.12779231369495392, -0.026913492009043694, -0.18460917472839355, 0.11700666695833206, -0.008049553260207176, -0.07663976401090622, 0.167732834815979, -0.014296013861894608, -0.0897468775510788, -0.005642749834805727, -0.1672038584947586, -0.061046499758958817, 0.24137455224990845, -0.1277538537979126, 0.005996344145387411, 0.051259253174066544, 0.07148891687393188, -0.0061117373406887054, -0.06945335119962692, 0.071808822453022, 0.006475712638348341, 0.21915726363658905, -0.07375087589025497, -0.1920320689678192, 0.015519590117037296, -0.09663143008947372, 0.046338777989149094, 0.0578354112803936, -0.16296151280403137, -0.272739976644516, -0.030021702870726585, -0.10345374792814255, 0.0656069666147232, 0.03738259896636009, -0.09842678159475327, 0.1251743733882904, 0.0253281369805336, 0.054364580661058426, -0.15681366622447968, 0.11415916681289673, 0.10134128481149673, -0.08954530954360962, 0.17211247980594635, -0.19726011157035828, 0.05280229449272156, 0.05120287463068962, 0.03838079050183296, 0.27290064096450806, 0.09909221529960632, 0.02401205711066723, 0.0614648200571537, -0.25811347365379333, -0.18005307018756866, -0.05716769024729729, 0.2730260193347931, -0.03294605389237404, 0.12473585456609726, -0.018285496160387993, 0.090085968375206, 0.10238915681838989, -0.026377271860837936, -0.13986679911613464, 0.15389029681682587, -0.08626231551170349, 0.04256344586610794, 0.11260966211557388, -0.10630697757005692, 0.015033962205052376, -0.1868753582239151, -0.027743462473154068, -0.08743899315595627, 0.06493458896875381, -0.06899744272232056, 0.010709909722208977, 0.057845477014780045, -0.04284144192934036, 0.128018319606781, -0.10845315456390381, -0.003599410178139806, 0.13166943192481995, 0.15052145719528198, 0.1382312923669815, -0.07081342488527298, 0.04781288281083107, 0.24540942907333374, 0.04334493726491928, -0.12942227721214294, 0.3146156966686249, -0.20591148734092712, 0.04991041496396065, 0.19565489888191223, -0.03838376700878143, 0.06999433785676956, -0.0961795523762703, -0.14825017750263214, -0.15971601009368896, 0.014583706855773926, 0.13211949169635773, -0.17016586661338806, 9.690527839681296e-33, 0.09128900617361069, 0.11486516147851944, 0.11103632301092148, -0.058092325925827026, -0.059768058359622955, 0.04400787875056267, 0.11764339357614517, -0.2577243745326996, -0.30679771304130554, 0.022520769387483597, -0.20127055048942566, 0.1984328180551529, 0.026656392961740494, 0.28953492641448975, -0.12131421267986298, -0.09008539468050003, -0.022691955789923668, -0.0680655837059021, 0.070780448615551, 0.09769907593727112, 0.2264823466539383, -0.005782110616564751, -0.06177907809615135, 0.0803605169057846, 0.08790406584739685, 0.07777771353721619, 0.03624808415770531, -0.004446724429726601, 0.20801153779029846, 0.12841814756393433, -0.12422042340040207, 0.018067441880702972, -0.0650564581155777, -0.14440511167049408, -0.01267124805599451, 0.11379905790090561, 0.04694834724068642, -0.0844491496682167, 0.010175446979701519, 0.1004524752497673, 0.2729186713695526, -0.0231627207249403, -0.20097069442272186, -0.30285438895225525, 0.13997536897659302, 0.03989258408546448, -0.1177874505519867, -0.18640869855880737, 0.08974980562925339, -0.042521219700574875, -0.08839280158281326, 0.03277098760008812, -0.1786346286535263, -0.0644889771938324, 0.05041074752807617, -0.09998025000095367, -0.12263908237218857, -0.07766487449407578, 0.11190707236528397, 0.06957796961069107, 0.08101045340299606, -0.03126300498843193, -0.023057138547301292, 0.13761985301971436, 0.0007699728012084961, -0.08639667928218842, -0.11240425705909729, -0.12527337670326233, -0.24589687585830688, 0.0027902473229914904, 0.0764436349272728, -0.11195961385965347, 0.0005817402270622551, -0.03367774933576584, -0.11109961569309235, -0.17939059436321259, -0.20205660164356232, -0.04314463958144188, 0.14434237778186798, 0.1315220147371292, 0.06819970905780792, 0.06715616583824158, 0.026268532499670982, 0.04589731991291046, 0.15896520018577576, -0.05465051904320717, 0.023789310827851295, 0.025694506242871284, -0.11969342082738876, -0.10286072641611099, -0.12305852025747299, 0.06231892481446266, -0.23201864957809448, 0.18485510349273682, -0.27076196670532227, -1.2327645825311432e-32, -0.11943644285202026, -0.14537103474140167, 0.20899222791194916, -0.005741602275520563, -0.08714384585618973, -0.01387318130582571, 0.13576370477676392, 0.10600359737873077, 0.2752191722393036, 0.1595126986503601, 0.20950175821781158, 0.0460561066865921, -0.07190804928541183, 0.017021525651216507, 0.11317376792430878, -0.1425478160381317, -0.0026908705476671457, -0.036751843988895416, -0.06896664202213287, 0.2029869258403778, -0.030369000509381294, 0.18829962611198425, -0.16215400397777557, 0.05744468793272972, 0.023574814200401306, 0.10943901538848877, 0.15607716143131256, 0.17911870777606964, 0.04627177119255066, -0.12108013778924942, -0.11875097453594208, 0.15210874378681183, -0.334256649017334, 0.002187125151976943, 0.00906440056860447, -0.0814051702618599, 0.11874161660671234, -0.09504139423370361, -0.0007944979588501155, -0.1492079347372055, 0.04286768287420273, -0.15456931293010712, 0.02648230269551277, 0.02434465102851391, 0.23629878461360931, 0.033475205302238464, -0.03331812471151352, 0.0015007322654128075, 0.052033547312021255, -0.046264708042144775, 0.002350588096305728, -0.11653195321559906, 0.21834157407283783, -0.02398807369172573, -0.2736918032169342, -0.03219176083803177, -0.006559567991644144, -0.05879974365234375, 0.013637911528348923, -0.13802529871463776, 0.19236066937446594, 0.09707081317901611, -0.10175704956054688, -0.1836637258529663, -0.05537243187427521, 0.22810715436935425, 0.23973488807678223, 0.039484843611717224, 0.009556385688483715, -0.09074008464813232, -0.17340418696403503, 0.040181610733270645, -0.11641980707645416, -0.2718905210494995, 0.08166631311178207, 0.15632809698581696, -0.2334655523300171, 0.0707131028175354, -0.008406495675444603, -0.2118666023015976, -0.009771093726158142, -0.12478047609329224, 0.09480525553226471, 0.09268422424793243, 0.14718610048294067, -0.0666486993432045, -0.1095435842871666, -0.008427151478827, 0.08663901686668396, -0.04429519921541214, -0.19063246250152588, -0.2179136574268341, -0.18305957317352295, 0.11805377155542374, -0.07136082649230957, -1.0024250229889731e-07, 0.24185040593147278, -0.041018810123205185, 0.027849268168210983, -0.11859434098005295, -0.04012025520205498, 0.06037390977144241, -0.10572049766778946, -0.061508629471063614, 0.13966773450374603, 0.2912808060646057, 0.014473139308393002, 0.09803687036037445, -0.06671342998743057, 0.11841998249292374, -0.14448627829551697, 0.15754194557666779, 0.05232233926653862, 0.0660858005285263, -0.05996910110116005, -0.24512650072574615, -0.14264801144599915, 0.17549920082092285, 0.2010614275932312, 0.004489001352339983, 0.020006828010082245, -0.05118628591299057, -0.035804543644189835, -0.08086862415075302, 0.022678427398204803, -0.10240572690963745, -0.05196838080883026, 0.04604126140475273, 0.08928228169679642, 0.061294667422771454, 0.09329606592655182, -0.08729685842990875, 0.11586686968803406, -0.05114384740591049, 0.2505761682987213, -0.027585845440626144, 0.15479500591754913, -0.1380728781223297, 0.06031060591340065, -0.03946909308433533, -0.07447334378957748, -0.1576743870973587, -0.09520680457353592, -0.14138434827327728, 0.056967977434396744, -0.14763446152210236, 0.032524529844522476, -0.07962866872549057, -0.011864094994962215, -0.06551232188940048, -0.1353212296962738, 0.1946842521429062, -0.035435501486063004, -0.19880977272987366, 0.042939912527799606, 0.014720321632921696, 0.2013990879058838, -0.39038461446762085, 0.060137782245874405, -0.10768334567546844], "changes": {"1wk": 0.4999995231628418}}, {"text": "PREMIUM Climb Bio to Join Nasdaq Biotechnology Index MT Newswires Thu, Dec 19, 2024, 6:47 PM Climb Bio (CLYM) said Thursday it will be added to the Nasdaq Biotech Index as part of the annual re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLYM", "date": "2024-12-19T18:47:30", "sentiment": {"score": 0.041920462623238564, "confidence": 0.05520707741379738, "probabilities": {"positive": 0.05520707741379738, "negative": 0.013286614790558815, "neutral": 0.9315062761306763}}, "embedding": [-0.26817819476127625, -0.17611746490001678, 0.04473763331770897, -0.03462047129869461, 0.0865665078163147, 0.060165777802467346, -0.21055704355239868, 0.03217856585979462, 0.008972212672233582, -0.0028511250857263803, 0.0014822311932221055, 0.019555309787392616, -0.012610187754034996, 0.07514727115631104, 0.14910699427127838, 0.19987528026103973, -0.14820481836795807, 0.039729148149490356, 0.12484756112098694, -0.06626055389642715, -0.0656617283821106, -0.020582938566803932, 0.04195364564657211, 0.0027319700457155704, -0.08731350302696228, -0.08815144002437592, -0.11532957851886749, 0.164169579744339, 0.14496295154094696, -0.06672492623329163, -0.11392230540513992, 0.14412623643875122, 0.002063486725091934, -0.07205244898796082, 0.012727640569210052, -0.027426375076174736, -0.10613743960857391, -0.038581233471632004, 0.02854466438293457, 0.02697475627064705, 0.2211878001689911, -0.21767264604568481, -0.07587269693613052, 0.08242521435022354, -0.005299984011799097, -0.16647373139858246, -0.0459236279129982, -0.072525754570961, 0.061810851097106934, 0.13721928000450134, -0.14587530493736267, -0.18911391496658325, -0.030172064900398254, -0.08351196348667145, 0.0711602121591568, 0.16928185522556305, -0.2689397633075714, -0.20797687768936157, 0.041802406311035156, -0.18883557617664337, 0.1027093380689621, 0.00813896395266056, -0.14817416667938232, 0.1389954388141632, 0.15510064363479614, -0.08079811185598373, -0.017975972965359688, 0.2399279773235321, 0.11695738136768341, -0.08603569865226746, 0.1470227688550949, -0.058876048773527145, 0.022978011518716812, 0.013725979253649712, 0.11579499393701553, 0.3344918191432953, 0.1417417973279953, 0.01879728026688099, -0.0072706290520727634, -0.1720033437013626, -0.23241402208805084, -0.05269523710012436, 0.1529574692249298, -0.08442962169647217, 0.011890719644725323, -0.054899074137210846, 0.13719749450683594, -0.04771840199828148, -0.17956823110580444, -0.18308356404304504, 0.19139383733272552, -0.17996464669704437, 0.028162840753793716, 0.04746580123901367, -0.09804482012987137, 0.08688930422067642, -0.3089916706085205, -0.16076283156871796, -0.06533767282962799, 0.013250109739601612, -0.025502560660243034, -0.04542374238371849, -0.1766348034143448, 0.1654478758573532, 0.022968927398324013, -0.11013010144233704, 0.03021848388016224, 0.24450916051864624, 0.035182613879442215, 0.10830475389957428, 0.023168060928583145, 0.22876957058906555, 0.24893571436405182, -0.1267561912536621, -0.1501265913248062, 0.20683276653289795, -0.16904067993164062, 0.03088894672691822, 0.2687933146953583, -0.01708250492811203, 0.04387088492512703, -0.010327254422008991, -0.03786367177963257, -0.11515698581933975, 0.008269423618912697, -0.007845887914299965, -0.1066908910870552, 9.290809067207839e-33, 0.12243694067001343, 0.09700754284858704, 0.17399471998214722, -0.2029629647731781, -0.05294346436858177, 0.0888875424861908, 0.0053473240695893764, -0.31828340888023376, -0.28035685420036316, -0.010802661068737507, -0.3031145930290222, 0.3227270543575287, 0.036664821207523346, 0.1811378002166748, -0.16209456324577332, -0.27297863364219666, 0.122148796916008, 0.04552439600229263, 0.08294331282377243, 0.004393023904412985, 0.13745816051959991, 0.06480976939201355, -0.029072215780615807, 0.13770058751106262, 0.03326444700360298, 0.11756283044815063, 0.05962436646223068, -0.1484176218509674, 0.19835808873176575, 0.20744763314723969, -0.21989311277866364, 0.022567464038729668, -0.22706934809684753, -0.06220649555325508, 0.07057511806488037, 0.07369458675384521, 0.07733035087585449, -0.06926528364419937, 0.06627180427312851, -0.015537691302597523, 0.2230827361345291, -0.10308545082807541, -0.1268024444580078, -0.21528077125549316, -0.12963978946208954, 0.06063619628548622, 0.010683811269700527, -0.16635824739933014, 0.06794420629739761, -3.893120083375834e-05, -0.17406444251537323, -0.016226893290877342, -0.09602425247430801, -0.08259440213441849, -0.05533691495656967, -0.09957899898290634, -0.09523751586675644, -0.10124202072620392, 0.17306236922740936, 0.06406513601541519, 0.08813004195690155, 0.12446756660938263, -0.0038285444024950266, 0.14093799889087677, -0.13403184711933136, 0.014122533611953259, -0.14064696431159973, -0.1335844099521637, -0.04690412059426308, 0.16379831731319427, 0.09569622576236725, -0.04226212948560715, -0.038301702588796616, 0.03400343656539917, -0.01436325442045927, -0.08437950164079666, -0.22185397148132324, -0.11095280945301056, 0.18868334591388702, 0.07332521677017212, 0.12425446510314941, -0.028731944039463997, -0.05159072205424309, -0.12267885357141495, 0.19472701847553253, 0.04735898599028587, -0.11669289320707321, -0.00170211773365736, 0.08674897253513336, -0.01946345344185829, -0.15142594277858734, 0.036782894283533096, -0.032427314668893814, 0.141899973154068, -0.25798937678337097, -1.3245598180076188e-32, -0.051572516560554504, -0.22587798535823822, 0.2608197033405304, -0.10418964922428131, -0.0433882400393486, 0.019318444654345512, 0.10286850482225418, 0.06769269704818726, 0.09265843778848648, 0.15342700481414795, 0.1416804939508438, 0.11400848627090454, -0.07048294693231583, -0.07869479060173035, 0.22511912882328033, 0.053435202687978745, -0.08323055505752563, -0.1480352282524109, -0.1979375183582306, 0.13021670281887054, -0.16126759350299835, 0.19626936316490173, -0.2480076551437378, 0.22907519340515137, 0.16233061254024506, 0.04479916766285896, 0.15697474777698517, 0.3356513977050781, 0.11926985532045364, -0.16359929740428925, -0.15052281320095062, -0.03337160870432854, -0.4181308150291443, 0.12589611113071442, 0.02195647358894348, 0.17544157803058624, 0.3417997360229492, -0.01617162488400936, -0.11336308717727661, -0.07389155775308609, 0.09751573204994202, -0.10353068262338638, -0.15867969393730164, 0.10261200368404388, 0.19266776740550995, 0.037346310913562775, -0.06968271732330322, 0.0433097779750824, 0.0031267779413610697, -0.12725283205509186, -0.03825319558382034, 0.0049558766186237335, 0.35384082794189453, 0.05114532634615898, -0.15189149975776672, -0.03875497728586197, -0.05991975963115692, 0.031354136765003204, 0.15912841260433197, -0.19776159524917603, 0.17512032389640808, -0.011253869161009789, -0.1965852826833725, -0.1680542528629303, 0.021762501448392868, 0.014550309628248215, 0.13529136776924133, -0.030528131872415543, -0.25662127137184143, -0.08714662492275238, -0.1365930289030075, 0.04501136764883995, 0.007219154853373766, -0.2952938675880432, 0.06307712942361832, 0.21981281042099, -0.17287606000900269, -0.007031912915408611, -0.026877285912632942, 0.03728057071566582, -0.01631823554635048, -0.11020855605602264, 0.07822845876216888, 0.009254314936697483, 0.12238726019859314, -0.05252811312675476, 0.10521306097507477, 0.062258582562208176, -0.08518143743276596, -0.17969383299350739, -0.15066514909267426, -0.3858890235424042, -0.17786957323551178, 0.25398555397987366, -0.014126515947282314, -9.945377144049417e-08, 0.2163778841495514, -0.10780836641788483, 0.010881088674068451, -0.07219119369983673, 0.15569858253002167, 0.04034220427274704, -0.16969895362854004, 0.010925828479230404, 0.14308005571365356, 0.19708772003650665, 0.0712893009185791, 0.09938434511423111, 0.048036862164735794, 0.2513180375099182, -0.027725523337721825, 0.1934899240732193, 0.04126717150211334, 0.044682763516902924, 0.05038205161690712, -0.21356673538684845, -0.11941061168909073, 0.13125279545783997, 0.25592824816703796, 0.165794238448143, -0.009378291666507721, 0.014472351409494877, 0.038460876792669296, -0.0963878184556961, 0.11073095351457596, -0.10301724076271057, -0.021953478455543518, 0.05480682849884033, -0.03868541121482849, 0.14569824934005737, 0.022569196298718452, 0.07202640175819397, 0.14063473045825958, 0.1052912175655365, 0.05573838949203491, 0.10087472200393677, 0.17945359647274017, -0.10012571513652802, -0.026607714593410492, 0.07533936947584152, -0.08934886008501053, -0.0900929868221283, -0.1441207379102707, -0.00712429778650403, -0.01923179067671299, -0.3560957908630371, 0.02925925701856613, -0.1345568746328354, 0.00796368345618248, 0.06925925612449646, -0.059100501239299774, 0.1742025762796402, -0.11613930761814117, -0.20125028491020203, -0.10176298022270203, 0.03610208258032799, 0.22918497025966644, -0.2655419707298279, 0.0750286728143692, -0.21058009564876556], "changes": {"1wk": 16.41025258552716, "1mo": 0.0}}, {"text": "Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy Climb Bio, Inc. Thu, Jan 9, 2025, 3:00 PM 6 min de lectura En este art\u00edculo: CLYM Climb Bio, Inc. Transaction Expands Climb Bio\u2019s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs Preclinical Data Expected to be Shared Later in 2025 WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070, Mabworks) for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China. Climb Bio believes CLYM116 is a potential best-in-class approach to address significant unmet need in patients with IgA nephropathy and other B-cell mediated diseases. This transaction furthers Climb Bio\u2019s goal of becoming a leader in developing new treatment options for immune-mediated diseases, complementing the Company\u2019s anti-CD19 antibody, budoprutug. \"Adding CLYM116 to our pipeline represents a pivotal moment for Climb Bio as we advance our ambition of becoming a leader in developing best-in-class treatments for patients with immune-mediated diseases,\" said Aoife Brennan, President and CEO of Climb Bio. \"IgA nephropathy is the most common cause of glomerulonephritis worldwide, and we believe that inhibition of APRIL is both a clinically validated mechanism and potentially disease modifying approach for this indication. We look forward to rapidly advancing CLYM116 and sharing initial preclinical data later in 2025.\" CLYM116, an Fc-engineered anti-APRIL monoclonal antibody, has the potential to address limitations of APRIL-targeted therapeutics currently in development. CLYM116 utilizes a novel mechanism of action to prevent APRIL signaling, potently blocking binding of APRIL to its receptors and also promoting lysosomal APRIL degradation via a pH-dependent bind-and-release design. Through its unique binding profile, CLYM116 has the potential to enable more rapid, deep and durable inhibition of APRIL signaling and IgA depletion. CLYM116 was engineered to increase serum half-life, potentially enabling an improved exposure profile and less frequent dosing in patients. CLYM116 is currently in IND-enabling studies, and Climb Bio plans to share data from the ongoing preclinical studies later in 2025. \u201cMIL116 (now CLYM116) has been specifically designed to meet the needs of patients with IgA nephropathy and has shown promising data in several preclinical models,\u201d said Dr. Feng Li, Chairman of the Board and General Manager of Mabworks. \u201cWe are thrilled to partner with Climb Bio, given their focus on immune-mediated diseases, and leverage the capabilities and expertise of both organizations to advance this program to clinical trials as expeditiously as possible.\u201d La historia contin\u00faa Transaction Details Under the terms of the agreement, Climb Bio will make an upfront cash payment of $9 million to Mabworks, and will be required to make certain additional payments upon the achievement of specified development, regulatory and commercial milestones, and pay low- to mid-single digit tiered royalties on net sales outside of Greater China. Further details on Climb Bio\u2019s technology transfer and exclusive license agreement with Mabworks, CLYM116 and IgA nephropathy can be found in Climb Bio\u2019s latest corporate presentation, which is available under the heading \u201cInvestors & News\u201d at climbbio.com. Financial Update As of December 31, 2024, Climb Bio had cash, cash equivalents and\u00a0short-term marketable securities of approximately $212.9 million. Following its entry into the license agreement, Climb Bio anticipates that its existing cash resources will be sufficient to fund its planned operations, including the development of budoprutug and CLYM116, through 2027. About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company\u2019s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an APRIL-targeted monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com . Forward-Looking Statements This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; plans to optimize the administration of budoprutug; the anticipated benefits of Climb Bio\u2019s license agreement with Mabworks; the sufficiency of Climb Bio\u2019s cash resources for the period anticipated; and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cworking\u201d and similar expressions. Forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its license agreement with Mabworks; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio\u2019s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio\u2019s actual results to differ materially from those contained in the forward-looking statements, see the \u201cRisk Factors\u201d section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio\u2019s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio\u2019s views as of the date hereof and should not be relied upon as representing Climb Bio\u2019s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio\u2019s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law. Investors Chris Brinzey ICR Healthcare chris.brinzey@icrhealthcare.com 339-970-2843 Media Jon Yu ICR Healthcare jon.yu@icrhealthcare.com 475-395-5375 Ver comentarios Condiciones y Pol\u00edtica de privacidad Privacy Dashboard Historias recomendadas", "symbol": "CLYM", "date": "2025-01-09T15:00:00", "sentiment": {"score": 0.8017397783696651, "confidence": 0.8096799254417419, "probabilities": {"positive": 0.8096799254417419, "negative": 0.007940147072076797, "neutral": 0.18237988650798798}}, "embedding": [-0.30229443311691284, -0.12251180410385132, 0.033262379467487335, -0.22795522212982178, -0.02521747350692749, -0.041690852493047714, -0.06192954629659653, 0.19162937998771667, 0.0710391029715538, -0.010652939788997173, -0.1589396595954895, 0.02892095409333706, -0.05555962771177292, 0.14921405911445618, 0.03907967731356621, 0.24704566597938538, 0.031857237219810486, 0.08963119983673096, -0.11858687549829483, -0.08007775247097015, 0.021250788122415543, -0.09650783240795135, -0.028470518067479134, 0.11439870297908783, -0.15629950165748596, -0.07342105358839035, -0.12028597295284271, 0.08613094687461853, -0.09556253999471664, -0.11623057723045349, -0.04013112932443619, 0.2654159665107727, -0.01118534430861473, -0.086590975522995, 0.028027920052409172, 0.029466085135936737, -0.06976552307605743, -0.004959506914019585, -0.08497313410043716, -0.12902405858039856, 0.047809287905693054, -0.11206698417663574, -0.04184335842728615, -0.09197752922773361, 0.054413385689258575, -0.14507736265659332, -0.1312650740146637, 0.12207077443599701, -0.008129637688398361, 0.2661277651786804, -0.07409603893756866, -0.0987841859459877, -0.0416937954723835, 0.13555794954299927, 0.04520668089389801, 0.014868000522255898, -0.22320683300495148, -0.05768292769789696, 0.06302519887685776, -0.023480625823140144, 0.01622297614812851, 0.011019228026270866, 0.03579678758978844, 0.12290547788143158, 0.06856102496385574, -0.04292216897010803, -0.07555758953094482, 0.033143624663352966, 0.00866026058793068, -0.06614293158054352, 0.14362891018390656, -0.13235105574131012, -0.017970550805330276, 0.17613953351974487, 0.14277219772338867, 0.21691906452178955, 0.07245044410228729, 0.1376340389251709, 0.10253767669200897, -0.21728476881980896, -0.09960300475358963, 0.2213645577430725, 0.159867525100708, 0.05493278056383133, -0.06385535001754761, 0.028250649571418762, 0.030100541189312935, 0.21173766255378723, 0.011448693461716175, -0.013008966110646725, 0.07999604940414429, -0.06518802791833878, 0.08222714066505432, 0.18155348300933838, 0.004256905987858772, 0.050013791769742966, -0.15891359746456146, -0.14500419795513153, -0.013983630575239658, 0.021374844014644623, -0.06578350812196732, 0.11525791883468628, -0.018658122047781944, -0.04512183368206024, 0.09166693687438965, -0.1422867625951767, 0.0768110454082489, 0.06522111594676971, 0.011385990306735039, -0.01948675513267517, 0.031004304066300392, -0.0743679404258728, 0.13645733892917633, -0.06745345890522003, -0.06007767841219902, 0.17772847414016724, -0.1123327910900116, 0.054330937564373016, 0.20796816051006317, -0.02897225320339203, 0.13477471470832825, -0.09632764756679535, -0.09793158620595932, -0.07271044701337814, -0.0006709927693009377, 0.23855847120285034, -0.19388535618782043, 3.887752139408892e-33, 0.05622963234782219, -0.01072849053889513, 0.10387544333934784, 0.12520356476306915, -0.08721236884593964, -0.09169745445251465, 0.13729232549667358, -0.1087718978524208, -0.26326537132263184, -0.0038256151601672173, -0.06228884309530258, 0.11146858334541321, 0.04276531934738159, 0.19865642488002777, -0.05746966600418091, -0.11251170933246613, 0.05697353929281235, -0.056815072894096375, -0.011849634349346161, -0.018809828907251358, 0.18110713362693787, -0.02716463804244995, -0.03142622858285904, -0.02485170215368271, 0.10868865251541138, 0.12040582299232483, 0.01929537206888199, 0.035685181617736816, 0.10617679357528687, 0.06535893678665161, -0.02975275367498398, 0.08861075341701508, -0.016613487154245377, -0.10732404887676239, -0.00892335269600153, -0.06080642715096474, 0.039275944232940674, -0.12196429073810577, -0.031034165993332863, 0.09478893876075745, 0.08177435398101807, 0.04789075255393982, -0.2159605622291565, -0.16892731189727783, 0.20687013864517212, -0.06176108121871948, -0.1341586709022522, -0.13046623766422272, -0.030177313834428787, -0.04188733920454979, 0.06783649325370789, 0.03839803859591484, 0.019106758758425713, -0.0752875804901123, -0.06007913500070572, -0.042496249079704285, -0.0949949324131012, -0.10292303562164307, 0.1141299158334732, 0.0008071495685726404, 0.003045054152607918, 0.0703326016664505, -0.10662981867790222, 0.21825185418128967, -0.08016308397054672, -0.08773722499608994, -0.015792688354849815, -0.020603880286216736, -0.20641419291496277, 0.07964543253183365, 0.0001856512390077114, -0.17277096211910248, 0.08393722772598267, 0.03883487731218338, 0.1339714229106903, -0.12210699915885925, 0.0734054297208786, -0.020270921289920807, 0.07648277282714844, 0.08025261759757996, 0.07852950692176819, 0.1106351763010025, -0.07561549544334412, 0.08126585185527802, 0.021420616656541824, -0.14224988222122192, -0.07437209039926529, -0.053282856941223145, -0.10566379874944687, -0.08968532085418701, 0.1326870173215866, 0.019851014018058777, -0.06277130544185638, 0.2830464839935303, -0.18190735578536987, -6.717347774094577e-33, 0.07375791668891907, -0.1282893568277359, 0.11089833080768585, -0.07924982160329819, -0.0601934939622879, 0.06438002735376358, 0.22000278532505035, -0.1412593126296997, 0.1900859773159027, 0.009307242929935455, 0.07021930813789368, 0.03774576261639595, -0.12789538502693176, 0.023026995360851288, 0.050070587545633316, -0.0580630823969841, 0.034502945840358734, -0.03869413584470749, -0.1868983805179596, 0.20646090805530548, -0.005749206990003586, 0.2166791558265686, -0.20928749442100525, 0.006017919629812241, 0.029007507488131523, 0.11489029973745346, 0.12607304751873016, 0.16894319653511047, 0.06307019293308258, -0.089902862906456, -0.1491260826587677, 0.05649577081203461, -0.29100000858306885, -0.08701962232589722, -0.020847879350185394, 0.020498553290963173, 0.08299517631530762, -0.26871955394744873, 0.007930269464850426, -0.23197904229164124, 0.016779828816652298, -0.03352956846356392, -0.0275974590331316, 0.0024136174470186234, 0.15513375401496887, 0.05840405821800232, 0.05123140290379524, 0.11344058811664581, 0.06202723830938339, 0.05818513035774231, -0.043257102370262146, -0.03777244687080383, 0.1290370523929596, 0.024374578148126602, -0.06487157940864563, -0.020589224994182587, 0.04380301386117935, -0.06333094090223312, -0.02556212805211544, -0.050113558769226074, 0.05270824581384659, 0.062144916504621506, 0.11454566568136215, -0.08232404291629791, -0.04746101796627045, 0.2149854302406311, 0.1648438721895218, 0.021632641553878784, -0.044788558036088943, -0.1689044088125229, -0.08929787576198578, 0.02968517132103443, -0.04434497654438019, -0.16909196972846985, 0.006446775980293751, 0.08018603175878525, -0.1255326271057129, -0.08326957374811172, -0.0593411810696125, -0.058945149183273315, -0.14461587369441986, -0.033419154584407806, -0.01832488365471363, 0.09584940969944, 0.10372250527143478, 0.020577089861035347, -0.022347480058670044, 0.04144800454378128, 0.12361764907836914, 0.005179842002689838, -0.016308117657899857, -0.21206587553024292, -0.11685936152935028, 0.17786327004432678, -0.04302207753062248, -1.0022755247973691e-07, 0.213217630982399, -0.040859632194042206, -0.014887682162225246, -0.20357529819011688, -0.04532863572239876, -0.0858270674943924, -0.013527540490031242, 0.040210969746112823, 0.1166302040219307, 0.16965287923812866, 0.14690712094306946, 0.2294837087392807, -0.05251609534025192, 0.09436246752738953, -0.06877384334802628, 0.08762470632791519, 0.07896576076745987, -0.08906440436840057, -0.08921867609024048, -0.13380736112594604, -0.09946402907371521, 0.05713562294840813, 0.1490001231431961, 0.008533976972103119, 0.06796185672283173, -0.24634654819965363, -0.027376823127269745, -0.009503249078989029, 0.08783499896526337, -0.16706594824790955, -0.09349904954433441, 0.040618278086185455, 0.004945382475852966, 0.08324135839939117, 0.057469531893730164, 0.004272359423339367, 0.11519668251276016, 0.03924982622265816, 0.040819957852363586, 0.012455040588974953, 0.18441066145896912, -0.03551357984542847, -0.005122896283864975, -0.1473180055618286, -0.07654600590467453, -0.20253127813339233, -0.1421370655298233, -0.06950050592422485, -0.1017235517501831, -0.12018481642007828, -0.13932840526103973, -0.04616743326187134, -0.05669216811656952, -0.02484852261841297, -0.08568499982357025, 0.2251064032316208, -0.15298733115196228, -0.17006918787956238, 0.11623933911323547, -0.031217660754919052, 0.06869914382696152, -0.18636582791805267, 0.1164475679397583, -0.07267063111066818], "changes": {"1wk": 0.0}}, {"text": "Climb Bio to be Added to the Nasdaq Biotechnology Index Climb Bio, Inc. Thu, Dec 19, 2024, 3:00 PM 4 min read In This Article: CLYM Climb Bio, Inc. WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 \u2013 Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio\u2019s inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market\u00ae (Nasdaq\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December. For more information about the NASDAQ Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI . About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company\u2019s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com . Forward-Looking Statements This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; the anticipated benefits of the acquisition of Tenet Medicines, Inc.; expectations regarding budoprutug\u2019s therapeutic benefits, clinical potential and clinical development; plans to optimize the administration of budoprutug; and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cworking\u201d and similar expressions. Forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc.; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio\u2019s ability to advance budoprutug on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials of budoprutug; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio\u2019s actual results to differ materially from those contained in the forward-looking statements, see the \u201cRisk Factors\u201d section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio\u2019s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio\u2019s views as of the date hereof and should not be relied upon as representing Climb Bio\u2019s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio\u2019s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law. Story Continues Investors Chris Brinzey ICR Healthcare chris.brinzey@icrhealthcare.com 339-970-2843 Media Jon Yu ICR Healthcare jon.yu@icrhealthcare.com 475-395-5375 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLYM", "date": "2024-12-19T15:00:00", "sentiment": {"score": 0.047608254477381706, "confidence": 0.060079269111156464, "probabilities": {"positive": 0.060079269111156464, "negative": 0.012471014633774757, "neutral": 0.9274497032165527}}, "embedding": [-0.09035998582839966, -0.16657206416130066, -0.020923756062984467, -0.10440029203891754, -0.10499025136232376, 0.06913471221923828, -0.11325693130493164, 0.12170618772506714, 0.08545312285423279, 0.06253361701965332, -0.07293224334716797, 0.0429794117808342, -0.016279999166727066, 0.052708134055137634, -0.016112087294459343, 0.0811818316578865, -0.05822931230068207, 0.08241745829582214, -0.05611998587846756, 0.00973331555724144, 0.023313291370868683, 0.05008329823613167, 0.03153927996754646, 0.01779990829527378, -0.0752585157752037, -0.1394231617450714, -0.11908002942800522, 0.0676412507891655, -0.07799190282821655, -0.10589544475078583, 0.011751288548111916, 0.18111476302146912, 0.034300971776247025, -0.042891502380371094, 0.06638026237487793, -0.023231759667396545, -0.171676367521286, -0.02528875134885311, 0.08817298710346222, -0.03003091551363468, 0.10420973598957062, -0.09661784768104553, -0.1153658926486969, 0.05854540690779686, 0.11948738992214203, -0.06463242322206497, -0.05663617327809334, 0.022471297532320023, 0.04833291471004486, 0.09713730216026306, -0.1855752021074295, -0.06481322646141052, -0.025511818006634712, 0.0840272530913353, -0.022754520177841187, 0.010034171864390373, -0.18240812420845032, -0.09407399594783783, 0.08626991510391235, -0.0003589147236198187, 0.1205759271979332, 0.03386610373854637, 0.018717680126428604, 0.07120026648044586, 0.29811257123947144, 0.007173947989940643, -0.006083359010517597, 0.06464940309524536, 0.038893017917871475, -0.019038673490285873, 0.2296634465456009, -0.13726350665092468, -0.05462406948208809, 0.07598164677619934, -0.12509174644947052, 0.19347718358039856, 0.03311627358198166, 0.21311582624912262, 0.033529434353113174, -0.1376524716615677, -0.10325463116168976, 0.03317052498459816, 0.06699973344802856, -0.09121658653020859, -0.15682759881019592, -0.030627958476543427, 0.13159701228141785, 0.12667244672775269, -0.003060995601117611, 0.053756777197122574, 0.12540414929389954, -0.06684953719377518, 0.03850722312927246, 0.08004650473594666, 0.008455370552837849, -0.0394754558801651, -0.13862425088882446, -0.10475248098373413, 0.1468852311372757, -0.035618532449007034, 0.054636113345623016, 0.03106277622282505, -0.15474428236484528, 0.013378426432609558, -0.07510881870985031, -0.09363493323326111, 0.08241958171129227, -0.05491751432418823, 0.011367813684046268, 0.05776248872280121, -0.07500623166561127, 0.1728309690952301, 0.019151972606778145, -0.062329716980457306, -0.10688890516757965, 0.18600252270698547, 0.004139408934861422, 0.08288197219371796, 0.18976637721061707, -0.028661470860242844, 0.025319401174783707, 0.010347051545977592, 0.019815931096673012, -0.2169552445411682, -0.027565138414502144, 0.03158678486943245, -0.21510624885559082, 5.983754075841035e-33, 0.0026920177042484283, -0.03599106892943382, 0.11792318522930145, -0.0710882768034935, -0.06745005398988724, 0.007351009640842676, 0.0833268091082573, -0.10483045876026154, -0.2312006950378418, 0.07597682625055313, -0.17382413148880005, 0.13617633283138275, -0.03605751320719719, 0.0826094001531601, 0.03172888234257698, -0.15063726902008057, 0.07236805558204651, -0.054027900099754333, 0.027617912739515305, -0.12361560761928558, 0.047143951058387756, -0.001708025112748146, -0.07182857394218445, 0.11933724582195282, -0.038154203444719315, -0.022474929690361023, -0.041294511407613754, -0.06933698058128357, 0.032789383083581924, 0.10176993906497955, -0.02148035727441311, 0.021282974630594254, -0.10456103086471558, -0.10571694374084473, 0.03653259575366974, -0.033877208828926086, -0.06664346158504486, -7.392466068267822e-05, 0.11544071137905121, 0.06578822433948517, 0.05134712904691696, -0.03728582710027695, -0.0650845542550087, -0.1522751897573471, -0.01986631378531456, 0.06018618866801262, -0.08028268814086914, -0.05343226343393326, -0.05500418692827225, 0.0873827338218689, -0.12574613094329834, -0.0013448172248899937, 0.08591896295547485, -0.15695203840732574, 0.04289931431412697, 0.020929068326950073, -0.10358330607414246, -0.11965800076723099, 0.023592490702867508, 0.17287248373031616, -0.0393533855676651, 0.108446404337883, -0.13101647794246674, 0.07574277371168137, -0.2384471744298935, 0.12246756255626678, -0.07296229898929596, -0.02681439183652401, -0.13088692724704742, 0.16108179092407227, 0.06741948425769806, -0.06865043193101883, 0.13085918128490448, -0.017077423632144928, 0.10669456422328949, -0.13365858793258667, -0.009799135848879814, 0.003150089643895626, 0.030717745423316956, -0.010792003944516182, 0.06413082033395767, 0.03885345160961151, -0.11153842508792877, -0.001826306339353323, 0.07198129594326019, -0.030765820294618607, -0.0314532145857811, 0.046317096799612045, -0.021683793514966965, -0.04502129182219505, 0.03230603039264679, -0.01007724180817604, -0.07431212067604065, 0.21674011647701263, -0.0797145888209343, -6.894513874546696e-33, 0.0800705999135971, -0.14949849247932434, 0.05619700625538826, -0.0385790690779686, -0.012275044806301594, -0.044677045196294785, 0.1287703663110733, -0.043955445289611816, 0.050933703780174255, -0.04338535666465759, -0.010462361387908459, 0.05638246238231659, -0.044203948229551315, -0.012123353779315948, -0.0054513695649802685, 0.08484242856502533, -0.009192025288939476, -0.06434690952301025, -0.13188841938972473, 0.09137424826622009, -0.10288017243146896, 0.2079465091228485, -0.20225736498832703, 0.08559807389974594, 0.07062181830406189, 0.08806698024272919, 0.09516875445842743, 0.2227569818496704, 0.15250612795352936, -0.11606988310813904, -0.1206410825252533, -0.03583834692835808, -0.33873260021209717, 0.1420220583677292, -0.042957860976457596, 0.061817269772291183, 0.22320763766765594, -0.27329570055007935, 0.011598524637520313, -0.030771685764193535, 0.05337168276309967, 0.09184616804122925, -0.03240811824798584, 0.022124869748950005, 0.14962664246559143, 0.016156485304236412, -0.02153000794351101, 0.0529765710234642, 0.14379313588142395, -0.0068694232031702995, -0.004997371695935726, 0.048584818840026855, 0.1896917223930359, 0.10563233494758606, -0.05855066329240799, 0.040317602455616, -0.06268520653247833, -0.010654538869857788, -0.10460114479064941, -0.10540331155061722, 0.14912927150726318, -0.002737926784902811, 0.04508723318576813, 0.0013405606150627136, -0.03737092763185501, -0.021079696714878082, 0.10417480021715164, -0.018929019570350647, -0.08877262473106384, -0.10761690139770508, -0.046120233833789825, -0.11819691956043243, 0.12178955972194672, -0.1779513955116272, -0.06181224435567856, 0.14668332040309906, -0.08610990643501282, -0.04462326690554619, -0.0401972271502018, 0.0058716232888400555, 0.02628587745130062, 0.04903661459684372, -0.020705701783299446, 0.0636073648929596, 0.07031133770942688, 0.10303131490945816, 0.055723123252391815, 0.007520277053117752, -0.025787552818655968, -0.08922019600868225, -0.02744370326399803, -0.288732647895813, -0.06434736400842667, 0.2223304659128189, -0.010827101767063141, -1.0003461170526862e-07, 0.16151294112205505, -0.15815453231334686, -0.022595074027776718, -0.12130217999219894, 0.16363434493541718, -0.05651580169796944, -0.01666896417737007, 0.024798544123768806, 0.12749183177947998, 0.16141653060913086, 0.12650026381015778, 0.15593352913856506, -0.20448073744773865, 0.2000310868024826, -0.14822377264499664, 0.09867402911186218, -0.12152142077684402, -0.010486932471394539, 0.012250804342329502, -0.14625655114650726, -0.1691780686378479, 0.0836636871099472, 0.07523838430643082, 0.1251436471939087, 0.019933639094233513, -0.05302233248949051, 0.06511616706848145, -0.07311403006315231, 0.07835456728935242, -0.01812151074409485, 0.003339853137731552, 0.03375736251473427, 0.0408133864402771, 0.008023102767765522, -0.05817469581961632, -0.0030007220339030027, 0.1337321698665619, 0.09594570845365524, 0.024343669414520264, 0.12268689274787903, 0.08501636236906052, -0.037563636898994446, -0.022538982331752777, 0.0163030456751585, -0.011633707210421562, -0.13067388534545898, -0.2018996626138687, 0.14553767442703247, -0.016344018280506134, -0.2892497777938843, 0.0008301176130771637, -0.06280955672264099, -0.0972396582365036, 0.044394608587026596, -0.09076062589883804, 0.2644052505493164, -0.1468248963356018, -0.07790594547986984, -0.025495855137705803, -0.0403328612446785, 0.13212111592292786, -0.18256482481956482, 0.05634819716215134, -0.05919782444834709], "changes": {"1wk": 1.5384600336500307, "1mo": 0.0}}, {"text": "TEDCO's First Round of Equitech Growth Fund Awardees Unveiled PR Newswire Wed, Dec 11, 2024, 6:16 PM 2 min read 14 projects received grants to promote growth of Maryland's ecosystem and workforce development COLUMBIA, Md. , Dec. 11, 2024 /PRNewswire/ -- TEDCO , Maryland's economic engine for technology companies, announced the awardees for the first round of the new Equitech Growth Fund . A total of nearly $7 million will be distributed among the 14 projects located across Maryland . Of these awards, over $4.7 million will support six projects focusing on building Maryland's infrastructure, while more than $2.2 million will go towards eight entities supporting workforce development. The Equitech Growth Fund helps power inclusive, diverse growth across the state. TEDCO CEO Troy LeMaile-Stovall \"The new award opportunity generated interest from 75 driven applicants from across the state, each offering unique approaches to addressing critical needs in sectors such as life sciences, advanced manufacturing, artificial intelligence, cybersecurity, data analytics and quantum computing training,\" said Troy LeMaile-Stovall , TEDCO CEO . \"We want to thank each of the applicants for their dedication to Maryland's growth towards a sustainable and competitive ecosystem.\" The Equitech Growth Fund 2024 award cycle is projected to support training for more than 3,200 students studying information technology (IT), potentially place 2,500 of these students into jobs annually, and support the creation of more than 160 science, technology, engineering and math (STEM) jobs in Maryland during the first year alone. The 14 awarded projects for the first round of the Equitech Growth Fund include three (3) projects housed in Baltimore City , four (4) located in Montgomery County , two (2) located in Prince George's County , and one each (1) in Talbot , Allegany , Howard , Caroline and Washington County . The winning organizations were officially unveiled at the 2024 Entrepreneur Expo and include: Maryland Association of Community Colleges LaunchPort, LLC (received awards for two projects) Eastern Shore Entrepreneurship Center The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. CLYM Environmental Services, LLC Early Charm Ventures KID Museum The Coding School Health Tech Alley Escalate USA , Inc. University System of Maryland at Hagerstown Worksource Montgomery, Inc. TCecure, LLC As part of TEDCO's Cultivate Maryland initiative , the Equitech Growth Fund and Commission were established during the 2023 legislative session in response to a study outlining a need for more diversity and inclusion in Maryland's technology ecosystem. To address this need, the fund awards grants for infrastructure and workforce development initiatives supporting the state's economic competitiveness and growth. Learn more about the unique fund at tedcomd.com/funding/cultivate-maryland/equitech-growth-fund . Story Continues About TEDCO TEDCO , the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland . Learn more at www.tedcomd.com . Media Contact Tammi Thomas , Chief Development & Marketing Officer, TEDCO, tthomas@tedcomd.com (PRNewsfoto/TEDCO) Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/tedcos-first-round-of-equitech-growth-fund-awardees-unveiled-302329113.html SOURCE TEDCO View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLYM", "date": "2024-12-11T18:16:00", "sentiment": {"score": 0.3155040293931961, "confidence": 0.3253917992115021, "probabilities": {"positive": 0.3253917992115021, "negative": 0.00988776981830597, "neutral": 0.6647204160690308}}, "embedding": [-0.09037789702415466, -0.0269162654876709, 0.07752448320388794, -0.02798491343855858, 0.06205226480960846, -0.010208701714873314, -0.019150882959365845, 0.026461459696292877, -0.026422088965773582, 0.08448585867881775, -0.04494769126176834, 0.014654755592346191, 0.1189742386341095, 0.003961907234042883, -0.1285814493894577, 0.11114552617073059, -0.02095947042107582, -0.029732173308730125, -0.025306500494480133, -0.04967847093939781, 0.16840890049934387, -0.014929990284144878, 0.008330188691616058, -0.10673052072525024, 0.08921657502651215, 0.040526051074266434, 0.01873810961842537, -0.06730887293815613, -0.14501197636127472, 0.020595114678144455, 0.0016942238435149193, 0.08920127153396606, -0.026037268340587616, -0.01231992244720459, 0.06638388335704803, 0.0722392350435257, -0.004997301381081343, 0.08070266246795654, 0.025345414876937866, -0.004711463116109371, -0.07177227735519409, -0.007371217478066683, 0.028266454115509987, 0.006173417903482914, -0.05033273249864578, -0.17352496087551117, 0.024601534008979797, -0.05801175534725189, 0.022006148472428322, -0.09781569242477417, -0.025376439094543457, -0.105719193816185, 0.010372721590101719, 0.08213114738464355, -0.10961899161338806, -0.0076759615913033485, 0.044629644602537155, -0.01366142462939024, -0.11037033051252365, -0.0936342179775238, 0.037604205310344696, -0.01330162025988102, -0.0454302579164505, -0.033774539828300476, 0.06185561418533325, 0.05507712811231613, -0.04388042539358139, 0.06673981249332428, 0.0037257843650877476, -0.12832583487033844, 0.06164707988500595, -0.012114124372601509, 0.0051121520809829235, 0.09606331586837769, 0.1677161455154419, 0.09894178807735443, 0.11504754424095154, 0.14926111698150635, 0.23309528827667236, -0.048954568803310394, -0.016123339533805847, 0.05492998659610748, -0.026925507932901382, -0.06797801703214645, -0.1122945249080658, 0.10722455382347107, -0.06004515290260315, 0.07624372839927673, 0.11010777950286865, 0.05983307212591171, 0.03482188284397125, -0.07853639125823975, -0.122039295732975, 0.04169619828462601, -0.02461131103336811, -0.026576146483421326, -0.12424303591251373, -0.11141151934862137, -0.031791239976882935, 0.035790763795375824, -0.0065217693336308, 0.13674114644527435, 0.09292098134756088, -0.09438950568437576, -0.029156208038330078, -0.013651600107550621, 0.05529410019516945, 0.04398395121097565, 0.13600245118141174, -0.03715408220887184, -0.02879432775080204, 0.03225196525454521, 0.038844041526317596, -0.012513728812336922, -0.09192605316638947, 0.15666237473487854, -0.10564859211444855, 0.05285942927002907, 0.14266711473464966, 0.050148844718933105, 0.04547718167304993, 0.07814604043960571, -0.08505848795175552, -0.14735710620880127, 0.05856030434370041, -0.20999188721179962, -0.19896593689918518, 1.0731201069987929e-32, -0.026937663555145264, 0.046481676399707794, 0.09365372359752655, 0.11040233075618744, 0.012923920527100563, 0.0019984482787549496, 0.1365618109703064, 0.0386250801384449, -0.16312040388584137, -0.0953066349029541, -0.15979740023612976, 0.15143971145153046, -0.03298985958099365, 0.11424682289361954, 0.04715733230113983, -0.19728827476501465, -0.12832655012607574, 0.0917569175362587, 0.030572984367609024, 0.08458690345287323, 0.04645346477627754, -0.16656315326690674, -0.0039017824456095695, -0.0001715589314699173, 0.13529890775680542, 0.032738808542490005, -0.047881945967674255, 0.12165316939353943, 0.04262566938996315, 0.07431264221668243, -0.03809407353401184, 0.12275379151105881, -0.004624746739864349, -0.1147233173251152, -0.035410359501838684, -0.1771826446056366, -0.002178928814828396, -0.07376503944396973, 0.1525307297706604, -0.0017687048530206084, -0.038912031799554825, 0.12048698961734772, 0.045064352452754974, 0.05678311735391617, -0.0075134821236133575, -0.0430234894156456, 0.15102365612983704, 0.03497673571109772, 0.11930297315120697, 0.018787838518619537, 0.04359882324934006, -0.010188085958361626, 0.056455858051776886, -0.08155284821987152, -0.04935609549283981, -0.024287862703204155, -0.0026145228184759617, -0.011337307281792164, 0.15132948756217957, -0.0011687860824167728, -0.08258618414402008, 0.06989295780658722, -0.04894053190946579, 0.06461865454912186, 0.03654072806239128, 0.034793391823768616, 0.049811311066150665, 0.07493707537651062, 0.145956888794899, 0.1309749186038971, 0.029331600293517113, -0.09310272336006165, 0.032922253012657166, -0.06406233459711075, 0.011731814593076706, -0.07026522606611252, 0.017133694142103195, 0.0568501353263855, -0.012696574442088604, 0.08735036104917526, -0.02069668285548687, 0.02503497153520584, -0.07276152074337006, -0.09209448099136353, 0.06199255213141441, 0.053482748568058014, 0.05623987317085266, -0.00013458821922540665, 0.0322519987821579, -0.009490394964814186, 0.0998041033744812, -0.042926959693431854, -0.10740964114665985, 0.11499780416488647, -0.023528095334768295, -9.348582410498847e-33, -0.04974229261279106, -0.0339568629860878, -0.006397421471774578, -0.03125955909490585, 0.12662240862846375, -0.05031107738614082, 0.09519727528095245, -0.07526502013206482, 0.11026326566934586, 0.019550085067749023, 0.03512142598628998, 0.005150926299393177, -0.042251553386449814, 0.003231923095881939, -0.015310133807361126, -0.05050704628229141, -0.02505558356642723, -0.03634493052959442, -0.027052296325564384, 0.01827891170978546, 0.057927247136831284, 0.1603863686323166, -0.19903084635734558, -0.035971034318208694, 0.10199034214019775, -0.0049591283313930035, -0.11113552004098892, 0.07538760453462601, 0.07148756831884384, 0.061293624341487885, 0.03312605991959572, -0.005276811309158802, -0.17102545499801636, 0.167792409658432, -0.09308038651943207, -0.10145894438028336, 0.034604430198669434, -0.1630701720714569, 0.05004710704088211, -0.05803613364696503, 0.2239687740802765, -0.09854156523942947, -0.060632795095443726, 0.04248511791229248, 0.003719906322658062, -0.0354013592004776, -0.0018464084714651108, -0.052151795476675034, 0.05686628073453903, 0.04441455751657486, -0.04005200415849686, 0.058109626173973083, -0.01659904420375824, 0.009581112302839756, 0.02940923534333706, 0.004159578122198582, 0.02586895227432251, 0.03522175922989845, -0.00686392979696393, -0.03624330833554268, 0.012723753228783607, 0.049101606011390686, -0.015585951507091522, 0.08482996374368668, 0.006128907203674316, -0.11788079142570496, 0.10111348330974579, 0.0651736855506897, -0.1274956464767456, -0.06300726532936096, 0.010822144336998463, 0.06824430078268051, 0.05914532393217087, -0.22874319553375244, -0.11274990439414978, 0.1288413405418396, 0.03104262799024582, 0.03693317621946335, -0.20595158636569977, 0.017897913232445717, -0.03277812525629997, -0.07999865710735321, 0.006458232644945383, 1.7805024981498718e-05, -0.011681078933179379, 0.07085749506950378, 0.031746815890073776, -0.031038928776979446, -0.06758058071136475, 0.06071016192436218, -0.19272591173648834, -0.12113648653030396, -0.009602158330380917, 0.08276684582233429, 0.01699717715382576, -1.0016258045197901e-07, -0.02513774111866951, 0.0557531975209713, -0.08701810240745544, -0.04185377433896065, -0.009116504341363907, -0.01418061088770628, -0.058186568319797516, 0.10838425159454346, 0.03873724862933159, 0.009974821470677853, 0.1601717174053192, 0.004947653040289879, 0.0022811705712229013, 0.08933301270008087, 0.060311879962682724, -0.017432142049074173, -0.10554589331150055, -0.008786019869148731, -0.105733722448349, -0.13369131088256836, 0.02749730460345745, -0.01548624224960804, -0.04347967728972435, 0.030654242262244225, -0.05333960801362991, -0.06541009992361069, 0.024322060868144035, 0.07032908499240875, -0.06228887662291527, -0.0792197585105896, 0.0014449763111770153, -0.07905606180429459, -0.041461292654275894, -0.019846111536026, 0.05988535284996033, -0.06987643986940384, -0.02082025818526745, 0.04626072198152542, 0.080832839012146, 0.14004728198051453, -0.011149650439620018, -0.038679979741573334, 0.03900378942489624, -0.044474098831415176, -0.028553783893585205, -0.03887150064110756, -0.1959514021873474, 0.01917479746043682, 0.08126282691955566, -0.08307327330112457, -0.03771217167377472, -0.04669928178191185, -0.15235507488250732, -0.1489243507385254, 0.11288020014762878, 0.05706285685300827, -0.01477859914302826, -0.06472458690404892, -0.08954018354415894, -0.011168884113430977, 0.003865571692585945, -0.13050158321857452, 0.09510672092437744, 0.017012013122439384], "changes": {"1wk": -34.677414268906325, "1mo": -35.48386898298783}}, {"text": "Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board Climb Bio, Inc. Mon, Nov 11, 2024, 3:00 PM 6 min read In This Article: CLYM Climb Bio, Inc. WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio\u2019s Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine\u00ae, Enbrel\u00ae, Adcetris\u00ae, Tecfidera\u00ae, Alprolix\u00ae, Eloctate\u00ae and Spinraza\u00ae. As a CEO, he has successfully guided both private and public companies from development to commercialization and has overseen multiple successful mergers. \u201cI am thrilled to welcome Dr. Doug Williams to Climb Bio. As our incoming Chair of the Board, Doug\u2019s experiences over his 30 plus year career building and leading a range of biotechnology and pharmaceutical companies will offer critical perspective as we grow Climb Bio,\u201d said Aoife Brennan, President and CEO of Climb Bio. \u201cIn particular, Doug\u2019s expertise in immunology drug development will be very valuable as we pursue our mission to develop better treatments for the approximately 50 million patients in the U.S. and many more globally living with immune-mediated diseases.\u201d Dr. Williams previously served as the President of Research and Development at Sana Biotechnology and was CEO of Codiak BioSciences. He has also served as Executive Vice President of Research and Development at Biogen. Prior to Biogen he was CEO at ZymoGenetics and led its acquisition by Bristol Myers Squibb. He has also held a variety of leadership positions, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics (acquired by Pfizer in 2023), Senior Vice President and Washington Site Leader at Amgen and Executive Vice President and Chief Technology Officer and a member of the Board of Directors at Immunex (acquired by Amgen in 2021). Dr. Williams has served as a board member of more than a dozen public and private biotechnology companies and is currently Chair of the Board of AC Immune SA and a Director of Stablix. He holds a Ph.D. from the State University of New York at Buffalo, Roswell Park Division and completed a postdoctoral fellowship at Indiana University School of Medicine. Dr. Williams added: \u201cI am honored to be joining Climb Bio\u2019s Board at this exciting time as they work to advance budoprutug and build a leading immune-mediated disease focused company. I believe budoprutug has potential across a broad range of B-cell mediated diseases and provides a cornerstone for the company to expand. I look forward to working with the talented Climb Bio team and the board to help them advance their mission to develop therapeutics for patients with immune-mediated diseases.\u201d Story Continues \u201cI look forward to continuing to work with Aoife, the Climb Bio team, and other board members,\u201d stated Andrew Levin, a member of Climb Bio\u2019s Board and former Chair of the Board. \u201cIn the short time since acquiring Tenet Medicines, we have achieved a great deal. With the tremendous opportunity ahead, I am excited to transition the Chair role to Doug while remaining on the Board. Doug has incredible experience and a proven track record in building successful biotechnology companies and will be invaluable in guiding Climb Bio going forward. In addition, on behalf of the Board, I would also like to thank Liam for his valuable contributions and commitment to the Company through its transition.\u201d About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company\u2019s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com . Forward-Looking Statements This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; the anticipated benefits of the acquisition of Tenet Medicines, Inc.; expectations regarding budoprutug\u2019s therapeutic benefits, clinical potential and clinical development; plans to optimize the administration of budoprutug; and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cworking\u201d and similar expressions. Forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc.; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio\u2019s ability to advance budoprutug on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials of budoprutug; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio\u2019s actual results to differ materially from those contained in the forward-looking statements, see the \u201cRisk Factors\u201d section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio\u2019s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio\u2019s views as of the date hereof and should not be relied upon as representing Climb Bio\u2019s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio\u2019s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law. Investors Chris Brinzey ICR Healthcare chris.brinzey@icrhealthcare.com 339-970-2843 Media Jon Yu ICR Healthcare jon.yu@icrhealthcare.com 475-395-5375 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLYM", "date": "2024-11-11T15:00:00", "sentiment": {"score": 0.08902424667030573, "confidence": 0.10217605531215668, "probabilities": {"positive": 0.10217605531215668, "negative": 0.013151808641850948, "neutral": 0.8846721053123474}}, "embedding": [-0.13618269562721252, -0.14549629390239716, 0.009318068623542786, -0.13058358430862427, -0.07296168804168701, -0.0342266708612442, -0.10020308196544647, 0.1825457215309143, 0.1369268149137497, 0.07016240060329437, -0.21306192874908447, -0.010828247293829918, -0.08827577531337738, 0.11245733499526978, -0.03680991381406784, 0.16420713067054749, -0.08409836888313293, 0.09571964293718338, -0.09383954107761383, -0.02488391473889351, -0.025773480534553528, -0.05043495446443558, 0.07189377397298813, 0.025789525359869003, -0.08971396088600159, -0.013837466947734356, -0.08528439700603485, 0.06850268691778183, -0.14474384486675262, -0.12406125664710999, 0.10938826948404312, 0.05662498250603676, 0.06372049450874329, -0.11127114295959473, -0.0010306993499398232, 0.08874800056219101, -0.12593038380146027, 0.01863287389278412, 0.03885839134454727, 0.0017305901274085045, 0.09708546102046967, -0.018388381227850914, -0.13025647401809692, 0.04710663855075836, -0.09156757593154907, -0.15496422350406647, 0.0197211392223835, -0.07431385666131973, -0.02835354208946228, 0.10316351056098938, -0.12514641880989075, -0.0774221271276474, 0.06918159872293472, -0.08474293351173401, -0.03642522543668747, 0.07128768414258957, 0.025216244161128998, -0.09861744940280914, 0.05357975885272026, -0.016846220940351486, 0.07457539439201355, -0.0054746028035879135, -0.06882857531309128, 0.07419324666261673, 0.13726569712162018, -0.008034495636820793, -0.05053495243191719, -0.004632533993571997, 0.0013846484944224358, -0.08060619235038757, 0.08706806600093842, -0.08454297482967377, 0.06931179761886597, 0.07405303418636322, 0.09774699062108994, 0.1740584671497345, 0.13298866152763367, 0.1410675197839737, 0.07012829184532166, -0.13143113255500793, 0.05410921201109886, 0.05057568848133087, -0.010152805596590042, 0.015161223709583282, -0.0767284482717514, 0.023852739483118057, 0.06765228509902954, 0.08165845274925232, -0.09644469618797302, 0.021338798105716705, 0.12707650661468506, -0.05047032982110977, 0.08531972765922546, 0.0581706166267395, -0.01161517109721899, 0.08300301432609558, -0.08447237312793732, -0.09180190414190292, -0.01774257980287075, -0.0007444685325026512, -0.0639883428812027, 0.034776609390974045, -0.037052445113658905, -0.07297703623771667, -0.016150426119565964, -0.153272807598114, 0.10284402966499329, -0.01627967692911625, -0.004894065670669079, 0.050770074129104614, -0.04708946868777275, 0.011842669919133186, 0.03386542573571205, 0.08992930501699448, -0.0774945318698883, 0.05040927976369858, -0.07250910997390747, 0.08353441953659058, 0.159402534365654, -0.06352730095386505, 0.10789190232753754, 0.005237208679318428, -0.0038553935009986162, -0.08464560657739639, 0.020094681531190872, 0.024997714906930923, -0.09415856748819351, 4.7843384149795136e-33, 0.09289402514696121, 0.08377671241760254, 0.10913918167352676, -0.0013465508818626404, -0.013332358561456203, 0.06734278798103333, 0.055224962532520294, -0.11286032199859619, -0.14277642965316772, -0.049772053956985474, -0.16620641946792603, 0.06219569221138954, 0.05684040114283562, 0.09848016500473022, -0.1533418893814087, -0.05460863560438156, 0.07681681960821152, -0.15144869685173035, -0.12281176447868347, -0.045153360813856125, 0.06390455365180969, 0.068049855530262, -0.0911320373415947, 0.21278125047683716, 0.009534195996820927, -0.02281991019845009, -0.07189112156629562, 0.008181938901543617, 0.04475293308496475, 0.06828191876411438, -0.1398044377565384, -0.02988085150718689, -0.16247156262397766, -0.04153783246874809, 0.09989628195762634, -0.060879699885845184, 0.013042398728430271, -0.028707418590784073, 0.12132515758275986, 0.053778380155563354, 0.010049724020063877, 0.05138301104307175, 0.03360885754227638, -0.020009880885481834, -0.0992378294467926, 0.01095519308000803, 0.03916904330253601, -0.014084609225392342, 0.008006111718714237, 0.04138096794486046, -0.025644417852163315, -0.011771058663725853, 0.12628109753131866, -0.12241314351558685, 0.06294731795787811, -0.08270518481731415, -0.12450893223285675, -0.04647267237305641, 0.10416693240404129, 0.11275573819875717, 0.04366162046790123, 0.21609991788864136, -0.09234648942947388, 0.19894981384277344, -0.11460182070732117, -0.039396196603775024, -0.021069113165140152, -0.09290840476751328, -0.04966204613447189, 0.043551817536354065, -0.008078699931502342, -0.01371235866099596, 0.08240216970443726, 0.0024663726799190044, -0.10728096216917038, -0.07562866806983948, -0.02207295410335064, -0.023890532553195953, 0.03029816597700119, 0.022184252738952637, 0.0275874026119709, 0.04954604431986809, -0.06649444252252579, -0.0805903747677803, 0.01912090554833412, -0.07650721073150635, -0.08881353586912155, 0.007114836014807224, -0.03976321592926979, 0.09217162430286407, -0.012600569985806942, -0.13330966234207153, 0.042206838726997375, 0.12693360447883606, -0.06023591011762619, -8.193615864461763e-33, 0.010038083419203758, -0.13273778557777405, 0.2287498116493225, -0.14569896459579468, 0.02149433270096779, 0.019175102934241295, 0.13442789018154144, -0.11673857271671295, 0.06051672622561455, -0.13879194855690002, 0.07209351658821106, 0.15289852023124695, -0.005694765597581863, 0.025020677596330643, 0.03610166534781456, 0.07426749169826508, -0.010273173451423645, -0.12561607360839844, -0.11388224363327026, -0.05656366050243378, 0.00029970635659992695, 0.24544891715049744, -0.23049557209014893, 0.11659719049930573, 0.037094421684741974, 0.054321423172950745, 0.08680552989244461, 0.1537751704454422, 0.09389206767082214, -0.03606942668557167, -0.08779019862413406, 0.05698726326227188, -0.29018139839172363, 0.05886423587799072, -0.0367664098739624, 0.11397090554237366, 0.09103761613368988, -0.20784446597099304, -0.029629545286297798, -0.08586785942316055, 0.11152055859565735, -0.04759052395820618, -0.010195006616413593, 0.002857745625078678, 0.1508517563343048, 0.024715863168239594, -0.06906051933765411, 0.030565066263079643, -0.03986731916666031, -0.013119104318320751, -0.14109808206558228, 0.06401348859071732, 0.0030620708130300045, 0.006810469552874565, 0.06255485862493515, 0.008554949425160885, 0.032946452498435974, -0.06766466051340103, -0.021061765030026436, -0.11994873732328415, 0.06389834731817245, 0.000886404886841774, 0.10982365161180496, -0.06432946026325226, -0.07459639757871628, 0.07998217642307281, 0.10198526084423065, -0.027043728157877922, -0.05706092715263367, -0.09933435916900635, 0.00727826077491045, 0.0015987399965524673, -0.07138075679540634, -0.19912436604499817, -0.07559611648321152, 0.13009774684906006, -0.1826065182685852, -0.09112772345542908, -0.10561955720186234, 0.018863022327423096, -0.011284923180937767, -0.09317822754383087, 0.022321511059999466, 0.05585804209113121, 0.07449227571487427, 0.1249876618385315, 0.013039026409387589, -0.06977677345275879, -0.05431412160396576, -0.11799781024456024, -0.005812250077724457, -0.3001081943511963, -0.043388981372117996, 0.1432713270187378, 0.07661581039428711, -1.0060196586891834e-07, 0.1534760445356369, -0.09688162803649902, 0.0406959094107151, -0.13862314820289612, 0.08108529448509216, 0.018473152071237564, -0.04951145127415657, 0.006022521760314703, 0.14631220698356628, 0.1993514448404312, 0.05740790814161301, 0.14143645763397217, -0.051156096160411835, 0.12965992093086243, 0.04292721301317215, 0.14243529736995697, -0.04919922724366188, 0.10558868944644928, -0.03791102394461632, -0.005965939722955227, -0.12164370715618134, 0.05205470323562622, -0.003774288110435009, 0.11610965430736542, 0.04211796447634697, -0.10393720120191574, -0.014737974852323532, -0.05498826503753662, 0.0723496526479721, -0.007818176411092281, 0.04610246792435646, 0.006301663815975189, -0.010234696790575981, 0.09849525988101959, 0.055699266493320465, -0.14676181972026825, 0.08225777745246887, 0.055047810077667236, -0.048181839287281036, 0.09640027582645416, 0.08334679901599884, 0.029951971024274826, -0.07592561095952988, 0.07037075608968735, -0.11365416646003723, -0.11005973815917969, -0.06906881928443909, 0.13877584040164948, -0.0005964078009128571, -0.21308667957782745, -0.021366311237215996, 0.03754199668765068, -0.0550951324403286, 0.021284194663167, -0.022565696388483047, 0.16156123578548431, -0.11233092844486237, -0.06864083558320999, -0.10836006700992584, 0.005993189290165901, -0.011746817268431187, -0.16243673861026764, 0.10420242697000504, -0.06890273094177246], "changes": {"1wk": -25.862068155533947, "1mo": -24.137931844466053}}, {"text": "Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights Climb Bio, Inc. Wed, Nov 13, 2024, 12:05 AM 9 min read In This Article: CLYM Climb Bio, Inc. Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls Highlights Timing of Key Upcoming Milestones Cash Runway Remains through 2027 Expected to Enable Delivery of Key Value Inflection Points WELLESLEY HILLS, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2024 and provided a business update. \u201cWe have had a very productive third quarter, successfully completing the rebranding and transition of Climb Bio into a leading immune-mediated diseases company,\u201d said Aoife Brennan, President and CEO of Climb Bio. \u201cAt our recent investor event, we outlined our development strategy and the broad potential of budoprutug. We have now received U.S. Food and Drug Administration clearance of our IND for our Phase 1b clinical trial of budoprutug in SLE and expanded our board and management team with the appointment of Dr. Doug Williams as Climb Bio's new board Chair and Dr. Gary Hao as Vice President of CMC. With a strong financial position and continued progress towards building our management team, we believe we are well-positioned to develop improved treatments for the approximately 50 million patients in the U.S. and many more globally living with immune-mediated diseases.\u201d Recent Highlights FDA Clearance of our IND for budoprutug in SLE. The U.S. Food and Drug Administration (FDA) has cleared the IND allowing Climb Bio to initiate a Phase 1b open label clinical trial of budoprutug in patients with active lupus. The trial is designed to evaluate the safety and impact of ascending dose regimens on the speed and depth of depletion of circulating B cells, the decline in production of pathogenic autoantibodies, and the nature of B cell subsets that are produced upon recovery of B cells. In addition, patients will be followed for changes in clinical outcomes. Continued focus on building a leading immune-mediated disease company. Appointed Doug E. Williams, Ph.D. as Chair of the Board of Directors. Dr. Williams boasts over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, he has held pivotal research and development roles, contributing significantly to the creation of groundbreaking drugs such as Leukine\u00ae, Enbrel\u00ae, Adcetris\u00ae, Tecfidera\u00ae, Alprolix\u00ae, Eloctate\u00ae and Spinraza\u00ae. As a CEO, he has successfully guided both private and public companies, from clinical development to commercial success, and has overseen multiple successful mergers. Additionally, he serves as Chair of the Board for both AC Immune SA and a director of Stablix. Dr. Williams holds a Ph.D. from the State University of New York at Buffalo, Roswell Park Division, and completed a postdoctoral fellowship at Indiana University School of Medicine. Appointed Gary\u00a0Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls (CMC). Dr. Hao has over 17 years of experience in biopharmaceutical CMC development, from discovery to commercialization. He has extensive regulatory filing experience and has led cross functional teams. Dr. Hao has held similar roles at multiple biotechnology companies, including Vesigen Therapeutics, Codiak BioSciences, TG Therapeutics, and Alkermes. Dr. Hao received a Ph.D. from the Joan & Sanford I. Weill Medical College of Cornell University and a B.S. in Biochemistry from Nakai University. Story Continues Presented additional data from the Phase 1b study of budoprutug in primary membranous nephropathy (pMN) at the American Society of Nephrology Kidney Week 2024. The data presented included the complete remission of proteinuria in 3/5 (60%) of patients dosed with budoprutug in the study. In addition, the data showed a rapid and significant reductions in anti-PLA2R autoantibodies, a key driver of pMN, with serological remission occurring in the 3 patients that were PLA2R positive at baseline. All patients in the study who received budoprutug saw a complete and sustained B-cell depletion, with undetectable levels of B-cells occurring after just two doses of study drug as low as 100 mg. Budoprutug was generally well-tolerated, with no reported drug-related serious adverse events. Program Overview and Anticipated Key Milestones pMN: pMN is an IgG4 mediated disease, affecting approximately 70,000 people. We have completed a Phase 1b trial in pMN and plan to continue the advancement of budoprutug for pMN to late phase development in 2025. Immune Thrombocytopenia (ITP): ITP is an IgG 1-3 immune-mediated disorder affecting an estimated 60,000 adults in the U.S. and where there is compelling proof-of-concept validating the clinical rationale for using B-cell depletion therapies. We plan to initiate a Phase 2 clinical trial of budoprutug in ITP in the first half of 2025 subject to regulatory clearance. SLE: SLE is a complex, chronic systemic disease opportunity affecting multiple organ systems, leading to significant morbidity and mortality that affects approximately 200,000 to 300,000 people in the U.S. Following the FDA clearance of our IND, we plan to initiate a Phase 1b clinical study of budoprutug for SLE in the first half of 2025. Advancement of subcutaneous formulation of budoprutug: Budoprutug has been successfully formulated above 175 mg/ml while maintaining low viscosity, creating an opportunity to pursue a subcutaneous dosing form that potentially features a low volume injection. The Company plans to continue to advance the subcutaneous formulation clinical program, with non-clinical data expected in the first half of 2025. Third Quarter Financial Results Cash Position: Cash, cash equivalents and marketable securities were $217.9 million as of September 30, 2024, as compared to $106.8 million as of December 31, 2023. Cash is expected to fund operations through 2027. Research and Development (R&D) expenses: R&D expenses were $6.2 million for the three months ended September 30, 2024, compared to $2.9 million for the same period in 2023. General and Administrative (G&A) expenses: G&A expenses were $5.5 million for the three months ended September 30, 2024, compared to $2.1 million for the same period in 2023. Other income, net: Other income, net was $2.8 million for the three months ended September 30, 2024, compared to $1.0 million for the same period in 2023. Net loss: Net loss was $8.9 million for the three months ended September 30, 2024, compared to $4.0 million for the same period in 2023. About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company\u2019s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com . Forward-Looking Statements This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding budoprutug\u2019s therapeutic benefits, clinical potential and clinical development; the trial design for the planned clinical trials of budoprutug; plans to optimize the administration of budoprutug; the anticipated timelines for initiating clinical trials of budoprutug; the sufficiency of Climb Bio\u2019s cash resources for the period anticipated and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cworking\u201d and similar expressions. Forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc.; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio\u2019s ability to advance budoprutug on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials of budoprutug; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio\u2019s actual results to differ materially from those contained in the forward-looking statements, see the \u201cRisk Factors\u201d section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio\u2019s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio\u2019s views as of the date hereof and should not be relied upon as representing Climb Bio\u2019s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio\u2019s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law. Investors Chris Brinzey ICR Healthcare chris.brinzey@icrhealthcare.com 339-970-2843 Media Jon Yu ICR Healthcare jon.yu@icrhealthcare.com 475-395-5375 Climb Bio, Inc. Condensed Consolidated Balance Sheets (In thousands) (unaudited) September\u00a030, 2024 December\u00a031, 2023 Assets Cash, cash equivalents, and marketable securities $ 217,927 $ 106,798 Other assets 4,272 3,671 Total assets $ 222,199 $ 110,469 Liabilities and stockholders\u2019 equity Liabilities 3,423 2,870 Total stockholders\u2019 equity 218,776 107,599 Total liabilities and stockholders\u2019 equity $ 222,199 $ 110,469 Condensed Consolidated Statements of Operations (In thousands, except per share amounts) (unaudited) Three Months Ended September\u00a030, Nine Months Ended September\u00a030, 2024 2023 2024 2023 Operating expenses: Acquired in-process research and development, related party $ \u2014 $ \u2014 $ 51,659 $ \u2014 Research and development 6,240 2,876 8,377 12,284 General and administrative 5,492 2,125 11,073 22,869 Total operating expenses 11,732 5,001 71,109 35,153 Loss from operations (11,732 ) (5,001 ) (71,109 ) (35,153 ) Other income, net 2,837 1,033 5,628 3,675 Net loss $ (8,895 ) $ (3,968 ) $ (65,481 ) $ (31,478 ) Net loss per share, basic and diluted $ (0.13 ) $ (0.15 ) $ (1.57 ) $ (1.17 ) View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLYM", "date": "2024-11-13T00:05:00", "sentiment": {"score": 0.7348131351172924, "confidence": 0.7461430430412292, "probabilities": {"positive": 0.7461430430412292, "negative": 0.011329907923936844, "neutral": 0.24252700805664062}}, "embedding": [-0.15417727828025818, -0.1237102672457695, 0.03625181317329407, -0.03465886041522026, -0.09150056540966034, -0.021538767963647842, -0.11848506331443787, 0.28938764333724976, 0.1067935973405838, 0.06852014362812042, -0.10568388551473618, 0.04742737486958504, -0.035119447857141495, 0.05801795423030853, -0.018264740705490112, 0.11527585238218307, 0.05935337394475937, 0.009141957387328148, -0.08319277316331863, -0.02854624018073082, -0.028215356171131134, -0.10612450540065765, 0.030522624030709267, 0.07767071574926376, -0.07208750396966934, -0.004785329103469849, -0.18131579458713531, 0.034586355090141296, -0.12987910211086273, -0.10925672948360443, 0.022838860750198364, 0.10912436991930008, 0.000859726220369339, -0.02472234144806862, -0.013265744782984257, -0.032313693314790726, -0.15667729079723358, 0.004279918037354946, 0.018855061382055283, -0.05445491150021553, 0.10878626257181168, -0.11755063384771347, -0.12453989684581757, 0.0052748993039131165, 0.023308217525482178, -0.08767388015985489, -0.10955917835235596, 0.06458920240402222, -0.021159110590815544, 0.18864360451698303, -0.0703827291727066, -0.07883951812982559, 0.07102963328361511, 0.06504897028207779, -0.07984930276870728, 0.04928375408053398, -0.060939986258745193, -0.08697056025266647, 0.05646996572613716, 0.02003207430243492, -0.06872907280921936, -0.010016296058893204, -0.0674702525138855, 0.03081624209880829, 0.06719551980495453, -0.051107123494148254, -0.0767831951379776, -0.03157642483711243, -0.028066610917448997, -0.013770636171102524, 0.13305239379405975, -0.06614071875810623, 0.028258895501494408, 0.07505882531404495, 0.08143691718578339, 0.16598421335220337, 0.06235404312610626, 0.17385584115982056, 0.06490357220172882, -0.10014072060585022, 0.1174604669213295, 0.13366463780403137, 0.11584803462028503, -0.003665358992293477, -0.08964705467224121, -0.008142962120473385, 0.0026270728558301926, 0.14809970557689667, -0.09577446430921555, 0.0304787065833807, 0.11920548975467682, -0.053067851811647415, 0.07589127123355865, 0.0743941217660904, -0.02470538392663002, 0.05163991451263428, -0.11058695614337921, -0.07766571640968323, 0.042353443801403046, 0.006655233912169933, -0.08008067309856415, -0.017232414335012436, -0.024762257933616638, -0.1404419243335724, -0.0033389078453183174, -0.15807722508907318, 0.04421524703502655, -0.11769871413707733, 0.03732999041676521, -0.0057183075696229935, 0.04953235015273094, 0.04025917872786522, 0.08161979168653488, 0.012737870216369629, -0.023654509335756302, 0.11502481997013092, -0.03940684720873833, -0.004208867438137531, 0.12325845658779144, -0.0545935221016407, 0.12421845644712448, -0.011663580313324928, 0.03905310481786728, -0.13321179151535034, 0.032056089490652084, 0.06563073396682739, -0.06528320908546448, 5.033505748471406e-33, 0.07768091559410095, -0.007533096708357334, 0.05036718398332596, 0.03128965571522713, -0.05721782147884369, 0.01918269693851471, 0.05476929992437363, -0.09398400038480759, -0.17261452972888947, -0.02485215850174427, -0.14392173290252686, 0.10440114885568619, 0.033837903290987015, 0.12556888163089752, -0.05093900486826897, -0.012799296528100967, 0.04670612886548042, -0.02385404333472252, -0.027600567787885666, -0.0907338410615921, 0.08997464925050735, -0.1423371136188507, -0.010343138128519058, 0.0631299540400505, 0.0024880070704966784, 0.0951663926243782, -0.045400090515613556, -0.06019047647714615, 0.060081519186496735, 0.0409555546939373, -0.09921161830425262, 0.051879528909921646, 0.05597931146621704, -0.09470945596694946, -0.02807462215423584, -0.06933735311031342, -0.03264661505818367, -0.09869390726089478, 0.051469698548316956, 0.0011131248902529478, 0.07121821492910385, 0.09424139559268951, -0.08718964457511902, -0.09603649377822876, 0.0439843013882637, -0.010144977830350399, -0.10412620007991791, -0.12376371026039124, 0.015525048598647118, 0.061631813645362854, 0.02129148133099079, -0.04810278117656708, 0.12313993275165558, -0.0734252780675888, 0.027319148182868958, -0.032636597752571106, -0.09016142785549164, -0.09651213884353638, 0.0974961519241333, 0.06707969307899475, 0.035716842859983444, 0.14287808537483215, -0.07436730712652206, 0.037846118211746216, -0.12906935811042786, 0.04321994632482529, -0.09480652213096619, -0.09181186556816101, -0.236933171749115, 0.05724392831325531, 0.018141524866223335, -0.14626871049404144, 0.08407571166753769, 0.02264128252863884, 0.04224967211484909, -0.08453521132469177, 0.1211591586470604, 0.06788383424282074, 0.010662698186933994, 0.018823638558387756, 0.07891213148832321, 0.07260401546955109, -0.11377063393592834, 0.12014840543270111, 0.07310574501752853, -0.05357394739985466, -0.007458905689418316, -0.056937992572784424, -0.1240386962890625, -0.025149183347821236, 0.05770614743232727, -0.018987832590937614, 0.012832232750952244, 0.18729636073112488, -0.07157914340496063, -7.088517462206407e-33, 0.016780773177742958, -0.06854604184627533, 0.05744187533855438, -0.11469234526157379, 0.08856816589832306, 0.06309857964515686, 0.1324169933795929, -0.0774371474981308, 0.18829277157783508, 0.005017906427383423, 0.03650131821632385, 0.08990828692913055, -0.032763849943876266, 0.055230919271707535, 0.02221422642469406, 0.039246611297130585, 0.0009233397431671619, -0.11018216609954834, -0.094925656914711, 0.05893566831946373, -0.012901457957923412, 0.2003224939107895, -0.10602480173110962, 0.06841199100017548, 0.06650026142597198, 0.05525368079543114, 0.09375735372304916, 0.13421031832695007, 0.08707516640424728, -0.1273147016763687, -0.1741088181734085, 0.00623685959726572, -0.23568318784236908, -0.028184588998556137, -0.05423159897327423, 0.04143457114696503, 0.144210085272789, -0.1591651439666748, -0.031322624534368515, -0.10122741013765335, 0.06654773652553558, -0.06705448776483536, -0.0698539987206459, 0.00022440217435359955, 0.18641212582588196, 0.001575241214595735, 0.022172462195158005, -0.006302674300968647, 0.04480339586734772, -0.018746208399534225, -0.028863895684480667, 0.005280354060232639, 0.04572509229183197, 0.04022999852895737, -0.040763966739177704, -0.05899197608232498, -0.0020351826678961515, -0.08310772478580475, -0.12215756624937057, -0.12224811315536499, 0.012340448796749115, 0.05799631029367447, 0.06476700305938721, -0.0003256397321820259, 0.03903523087501526, 0.1554025113582611, 0.16226644814014435, -0.028725434094667435, -0.05854935199022293, -0.19586563110351562, -0.12000291794538498, 0.006343460641801357, -0.012511386536061764, -0.14563900232315063, 0.09156573563814163, 0.13661539554595947, -0.13806508481502533, -0.07846308499574661, -0.037747595459222794, 0.009159484878182411, -0.06226208806037903, -0.06695524603128433, -0.0680793821811676, 0.03088224120438099, 0.0606033131480217, 0.07875578850507736, -0.025913972407579422, 0.03431776911020279, 0.014979686588048935, -0.002424940699711442, -0.02803073637187481, -0.1739082634449005, -0.03420069068670273, 0.14227715134620667, 0.07061156630516052, -1.0067737576946456e-07, 0.22311462461948395, -0.04005170986056328, 0.04024924337863922, -0.10810142755508423, 0.04079582542181015, -0.01012854278087616, 0.011929193511605263, 0.008900109678506851, 0.06866342574357986, 0.1262257695198059, 0.012341555207967758, 0.17443040013313293, -0.07241488993167877, 0.05807061120867729, 0.0037710843607783318, 0.0885261595249176, -0.0325380302965641, 0.03864741325378418, -0.07056762278079987, -0.05442342534661293, -0.11549852043390274, 0.07438895106315613, 0.11982161551713943, 0.035982586443424225, 0.05914849415421486, -0.12235074490308762, 0.03797188773751259, -0.07625418156385422, 0.036290980875492096, -0.08724331855773926, 0.05332321673631668, 0.056408945471048355, 0.003002999583259225, 0.054096072912216187, 0.014599588699638844, -0.10175051540136337, 0.09250742942094803, 0.06172432377934456, 0.09756583720445633, 0.14501360058784485, 0.029430028051137924, 0.08178997039794922, -0.05987390875816345, 0.006204238161444664, -0.14510324597358704, -0.055399227887392044, -0.08650438487529755, 0.07444043457508087, 0.011894863098859787, -0.2379152774810791, -0.09182322770357132, -0.035883642733097076, -0.08937917649745941, -0.03673863410949707, -0.0966259241104126, 0.1771610826253891, -0.06323841214179993, -0.16378402709960938, 0.030179424211382866, -0.17306829988956451, 0.08714710175991058, -0.18698957562446594, 0.028756441548466682, 0.09575513005256653], "changes": {"1wk": -14.473683137312477, "1mo": -25.789474509759636}}, {"text": "The Glenlivet is Taking Back Tartan This Holiday Season as it Reweaves Heritage With a Modern Twist PR Newswire Mon, Dec 9, 2024, 5:00 PM 7 min read In This Article: PDRDF PRNDY The iconic single malt Scotch whisky brand and Thomas Doherty are leading a modern-day Scottish renaissance in American culture with the introduction of The Glenlivet tartan NEW YORK , Dec. 9, 2024 /PRNewswire/ -- The Glenlivet, the definitive Speyside single malt Scotch, enlists actor Thomas Doherty to introduce The Glenlivet tartan in the ultimate expression of Scottish sophistication, bringing quality and refinement from Speyside to stateside this holiday season. With the new The Glenlivet tartan, the single malt Scotch and Doherty are reimagining tartan for a contemporary Scotland , as the pattern originally established in the Scottish Highlands centuries ago to represent kinship and family takes over today's runways and red carpets. Pathing the way for a modern Scottish Renaissance, The Glenlivet and Doherty are introducing new fashion-forward expressions of The Glenlivet tartan and The Glenlivet Tartan Tini cocktail, inspiring originality in both style and flavor in time for holiday celebrations. The Glenlivet (PRNewsfoto/Pernod Ricard USA) The Glenlivet and Thomas Doherty both share a respect for the codes of quality that make Scotch superior met with propensity for elevating and evolving traditions in the name of propelling forward. As such, the two icons of Scottish excellence set forth to reweave heritage this holiday and encourage fans to embrace spins on beloved classics from holiday dressing to whisky cocktails. An embodiment of the influence of Scotland in modern culture, Doherty originally hails from Edinburgh , just miles away from the birthplace of the iconic single malt and currently resides in NYC where he has stood out with an undeniable sense of style, often sporting elevated takes on traditional silhouettes. \"What a gift it is to be Scottish. When I think about my heritage, I feel a deep sense of pride and connection to something much older and deeper than myself. It's been so rewarding to work with The Glenlivet on this project that pays homage to the next generation of Scottish craftsmanship,\" said Thomas Doherty , actor and The Glenlivet ambassador. \"The tartan print and The Glenlivet single malt scotch whisky are both so iconic to Scotland . It's been such a pleasure putting a modern spin on these Scottish symbols and sharing them with my friends in the U.S.\" Doherty and The Glenlivet have also brought together a collective of tastemakers to offer their own expressions of originality as The Glenlivet brings together the best of Scottish and American cultures. Starring alongside Doherty in striking new creative content, each member of the collective is inspiring their community to stand apart this holiday through their unique talents and perspectives: Story Continues NYC IT Girl Stylist Beverly Nguyen styled a variety of looks that spotlight The Glenlivet Tartan pattern across modern silhouettes \u2013 each ensemble spotlighted in the campaign content. Beverly as a definitive fashion tastemaker in NYC is also giving tips on how to style Scottish tartan in your own holiday wardrobe. Celebrated artist Clym Evernden has created original illustrations that reflect The Glenlivet's 200 year history as an iconic symbol of whisky, standing among the New York City skyline to reflect how the brand has risen to modernity. Brooklyn -based DJ Amrit Tietz is bringing good vibes to holiday parties this season with her \"Tartan Tracks\" playlist , which features a blend of classic and new age songs while also highlighting Scottish musicians. The King of Soho style Maurice Kamara is delving into the tartan pattern's significance in culture sharing snippets from an interview with Doherty in his signature, off-the-cuff-style in street style content on @thepeoplegallery_ . With an unwavering mission to push the boundaries of creativity and flavor set forth by George Smith when he first established the brand in 1824, The Glenlivet commissioned\u00a0Lochcarron of Scotland , the world's leading manufacturer of authentic Scottish tartan, to design and produce The Glenlivet tartan. Featuring hand-stitched, amber-colored hues inspired by its warm liquid woven atop of The Glenlivet's iconic teal, The Glenlivet tartan sets a new standard for Scottish style as it looks forward to the next 200 years. \"As the #1 single malt Scotch whisky brand in the US 1 , The Glenlivet is proud to bring together a unique group of Scottish icons and American culture curators to celebrate the quality and craftmanship that make single malt special while leading the category forward as a modern day symbol of sophistication,\" said Johan Radojewski , Vice President Marketing - Scotch & Irish Whisk(e)y, Pernod Ricard USA . \"The surging of tartan pattern in American culture is a testament to consumers valuing heritage and high quality over fleeting trends. The cultural movement around new heritage shines a spotlight on the staying power of Scottish sophistication, and the quality and craftmanship that single malt stands for.\" The Glenlivet tartan will debut with a VIP launch party hosted with Thomas and his team of trendsetters at Soho's newest, celebrity-approved hotspot for an evening of elevated cocktails, art, music and standout style. The party will also serve as the kickoff to an array of tartan takeovers that will bring the design to life in unexpected ways for consumers to enjoy throughout New York City . Wrapped around the exterior of taxi cabs, adhered to sidewalks, popping up in tastemaker hotels through umbrellas and postcard mailboxes, and transforming iconic NYC locations through AI content, each unique tartan moment represents an invitation from The Glenlivet to stand out with a refined choice. Those outside of NYC can also stand apart with their fashion and whisky choices this season with The Glenlivet Speyside Meets Stateside Holiday Collection available on ReserveBar , which includes The Glenlivet 12 Year Old, The Tartan Tini cocktail recipe, tartan winter fashion accessories and a deck of cards to elevate holiday hosting and gifting. The \"Taking Back Tartan\" initiative comes as the pinnacle of The Glenlivet's yearlong bicentennial celebrations featuring bespoke collaborations, innovative and prestigious new whiskies, commemorative events and a new masterbrand campaign inspiring consumers to stand apart from the herd by making a more refined whisky choice. To join The Glenlivet, Thomas Doherty and friends in standing apart with sophisticated Scottish holiday soirees, visit https://www.theglenlivet.com/en-us/thomas-doherty-x-the-glenlivet/ and follow @TheGlenlivet_US. #TakingBackTartan ABOUT THE GLENLIVET Founded by George Smith in 1824, The Glenlivet is renowned for its heritage as a visionary within the single malt category. With a commitment to outstanding quality and craftsmanship within single malts, The Glenlivet is dedicated to continuing this legacy and has led innovation within the single malt category in recent years. Standout initiatives include the launch of The Glenlivet Fusion Cask a category-first innovation that offers an elevated, one-of-a-kind taste experience by selectively finishing The Glenlivet's iconic single malt Scotch whisky in bespoke casks that are uniquely crafted by fusing dismantled rum and bourbon barrels. The Glenlivet has also recently launched its newly renovated brand home to open up Speyside to the world. Using innovative technology combined with exclusive bottlings, immersive tours and whisky tastings, The Glenlivet Brand Home brings visitors an experience like no other. From exploring the art of whisky making and showcasing rare editions, to reflecting The Glenlivet's heritage throughout the interiors, the visitor experience pays homage to being the original mark of quality for Speyside single malt. ABOUT\u00a0PERNOD RICARD USA Pernod Ricard USA is the premium spirits and wine company in the U.S., and the largest subsidiary of Paris, France -based Pernod Ricard SA., the world's second largest spirits and wine company. Pernod Ricard employs approximately 19,000 people worldwide, is listed on Euronext (Ticker: RI) and is part of the CAC 40 index. The company's leading spirits include such prestigious brands as Absolut Vodka, Avi\u00f3n Tequila, Chivas Regal Scotch Whisky, The Glenlivet Single Malt Scotch Whisky, Jameson Irish Whiskey, Kahl\u00faa Liqueur, Malibu, Martell Cognac, Olmeca Altos Tequila, Beefeater Gin, Del Maguey Single Village Mezcal, Co\u0301digo Tequila, Monkey 47 Gin, Seagram's Extra Dry Gin, Malfy Gin, Hiram Walker Liqueurs, Midleton Irish Whiskey, Redbreast Irish Whiskey, Aberlour Single Malt Scotch Whisky, Lillet, Jefferson's Bourbon, TX Whiskey, Skrewball Whiskey, Smooth Ambler Whiskey, Rabbit Hole Whiskey, Pernod and Ricard; such superior wines as Jacob's Creek, Kenwood Vineyards, Campo Viejo , Brancott Estate and Sainte Marguerite en Provence Ros\u00e9.; and such exquisite champagnes and sparkling wines Perrier-Jou\u00ebt Champagne, G.H. Mumm Champagne, Mumm Sparkling. Pernod Ricard USA is headquartered in New York, New York , and has more than 1,000 employees across the country. As \"creators of conviviality,\" we are committed to sustainable and responsible business practices in service of our customers, consumers, employees and the planet. Pernod Ricard USA urges all adults to consume its products responsibly and has an active program to promote responsible drinking. For more information, visit: www.pernod-ricard-usa.com MEDIA CONTACT Jordan Serafino Strategic Brand Communications Manager, Pernod Ricard USA Jordan.Serafino@Pernod-Ricard.com Regina LoBiondo Articulate on behalf of The Glenlivet Regina@ToArticulate.com 1 #1 in $ sales - Nielsen 52 weeks ending 11/9/24, Total US xAOC + Liquor Open State + Conv; #1 in $ Sales - NABCA Control States, rolling 12 months ending Sept, 2024 The definitive Speyside single malt Scotch whisky brand and Thomas Doherty are leading a modern-day Scottish renaissance in American culture with the introduction of The Glenlivet tartan. Thomas Doherty and The Glenlivet brought together a collective of tastemakers to offer their own expressions of originality on The Glenlivet tartan, marrying the best of Scottish and American cultures. Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/the-glenlivet-is-taking-back-tartan-this-holiday-season-as-it-reweaves-heritage-with-a-modern-twist-302325577.html SOURCE Pernod Ricard USA View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLYM", "date": "2024-12-09T17:00:00", "sentiment": {"score": 0.10031429305672646, "confidence": 0.11875896155834198, "probabilities": {"positive": 0.11875896155834198, "negative": 0.018444668501615524, "neutral": 0.8627963066101074}}, "embedding": [-0.06841430068016052, -0.11722645163536072, 0.06557731330394745, -0.0559576153755188, 0.037731289863586426, -0.056786663830280304, 0.0561896488070488, -0.11105754971504211, -0.08625055104494095, -0.009988408535718918, 0.014479545876383781, 0.05174699425697327, 0.019294001162052155, 0.015482785180211067, 0.08597517013549805, 0.017207589000463486, -0.1326093226671219, 0.016157861799001694, -0.0030618011951446533, 0.1857755184173584, 0.05286093056201935, -0.050542935729026794, 0.006811750587075949, 0.09383229911327362, -0.05490636080503464, 0.018697448074817657, 0.005048922263085842, -0.00010921387001872063, -0.17046689987182617, -0.010826204903423786, -0.04954472929239273, 0.03240764141082764, -0.2873876690864563, -0.0445791631937027, -0.18646350502967834, 0.23089861869812012, -0.004214155487716198, 0.12308555841445923, 0.015519021078944206, -0.03662053495645523, -0.07884806394577026, -0.06704413145780563, -0.07980431616306305, 0.054101184010505676, 0.05744266137480736, 0.003961596172302961, 0.022852128371596336, 0.01173197478055954, 0.04021428897976875, 0.036989133805036545, -0.0771651417016983, 0.04497528448700905, -0.03925421088933945, -0.017527254298329353, 0.07347406446933746, -0.06665398925542831, -0.07419827580451965, -0.02963046357035637, 0.048255350440740585, -0.04860786348581314, -0.18757760524749756, -0.05725213885307312, -0.098316490650177, -0.07699737697839737, 0.13581621646881104, -0.06215158477425575, -0.004060334526002407, 0.0564739927649498, 0.00339503213763237, -0.13566432893276215, -0.019138388335704803, -0.055165618658065796, 0.08226706832647324, 0.11523505300283432, -0.021337978541851044, 0.03868947923183441, 0.062072452157735825, 0.036354247480630875, -0.19005392491817474, 0.06768098473548889, 0.11224660277366638, 0.11635001748800278, 0.04280261695384979, 0.08333009481430054, -0.051199980080127716, -0.04671044647693634, 0.0030018556863069534, -0.1493745893239975, 0.005065031349658966, 0.058489907532930374, -0.015497101470828056, 0.09327271580696106, -0.12402667105197906, -0.040199704468250275, 0.17928144335746765, -0.047053951770067215, -0.00463707884773612, 0.14945483207702637, -0.087515689432621, 0.11159485578536987, -0.055084194988012314, 0.05964874476194382, -0.070551797747612, -0.011799699626863003, 0.013972420245409012, -0.15520945191383362, -0.04035777226090431, -0.08666573464870453, -0.03274920582771301, -0.1248786449432373, 0.02806585654616356, 0.09215880930423737, -0.12990957498550415, -0.14890947937965393, -0.011955400928854942, 0.03728526085615158, -0.024142472073435783, 0.0626787543296814, 0.09642753005027771, -0.06644555926322937, 0.017555704340338707, 0.3405517637729645, 0.055924370884895325, -0.07424584776163101, -0.05486362427473068, 0.05467779189348221, 0.0005232319235801697, 8.9138001109083e-33, -0.047838471829891205, 0.13981348276138306, -0.047831594944000244, 0.10205438733100891, 0.02792927995324135, -0.03692401200532913, -0.14022494852542877, 0.031135063618421555, 0.050559334456920624, -0.09687978029251099, 0.09827840328216553, -0.05514099821448326, -0.1871698796749115, -0.07572516798973083, 0.01368289440870285, -0.08164577186107635, -0.05405547842383385, -0.09646476805210114, 0.005761130712926388, -0.0888328105211258, -0.11766234785318375, 0.12277095019817352, 0.1567492038011551, 0.0029000467620790005, -0.1723594069480896, 0.03030606359243393, 0.2093285620212555, 0.06533621996641159, -0.1188056543469429, 0.028923917561769485, 0.09371089935302734, 0.13769501447677612, -0.01821666769683361, -0.07353858649730682, 0.022313052788376808, -0.08507794141769409, -0.02895541675388813, -0.181008979678154, 0.08805350959300995, 0.1381954550743103, -0.17426416277885437, -0.0677446499466896, -0.037625331431627274, -0.04783153161406517, -0.07891403138637543, 0.018700651824474335, 0.05145537853240967, 0.09961889684200287, -0.033274389803409576, 0.09524382650852203, 0.10630038380622864, 0.03329884260892868, 0.010359198786318302, 0.018258124589920044, -0.17950201034545898, 0.002038062084466219, 0.06954389810562134, -0.20877882838249207, 0.16533488035202026, -0.09698465466499329, 0.0851244181394577, 0.04054392874240875, 0.15070979297161102, -0.06600623577833176, 0.052382685244083405, 0.12554150819778442, 0.10535120964050293, 0.03354378789663315, -0.027446962893009186, -0.017157552763819695, -0.04828885942697525, 0.005673792213201523, 0.06358834356069565, -0.10270456969738007, 0.05600275844335556, 0.10987836122512817, -0.026066986843943596, 0.12291251122951508, 0.22429776191711426, -0.05221607908606529, -0.17016617953777313, 0.03399926424026489, 0.04453606158494949, 0.10407999902963638, 0.04820908606052399, -0.07267799973487854, 0.12387081980705261, -0.1426316201686859, -0.022785423323512077, 0.04307086765766144, -0.07406100630760193, 0.011233935132622719, -0.09885796904563904, -0.11408942937850952, 0.06304662674665451, -1.1393994743491445e-32, 0.23211868107318878, -0.15788128972053528, -0.04990671947598457, 0.051358141005039215, -0.07374604791402817, -0.03588041663169861, 0.0018654013983905315, -0.07461455464363098, 0.057446740567684174, 0.08597061783075333, 0.0562894269824028, 0.0664677768945694, -0.01812233030796051, -0.08054740726947784, 0.007211513817310333, 0.07697556912899017, -0.026807675138115883, 0.1503327339887619, -0.03262827545404434, 0.03026949055492878, 0.16720445454120636, 0.21574239432811737, -0.21298043429851532, -0.030989870429039, -0.05189947783946991, -0.08289399743080139, 0.12225879728794098, 0.11051711440086365, 0.06500283628702164, -0.21007344126701355, 0.09798309952020645, -0.038117025047540665, 0.05099363252520561, -0.05224325880408287, 0.015666401013731956, 0.1833043396472931, 0.10858948528766632, -0.012825635261833668, -0.012421802617609501, 0.1568937599658966, 0.07638780772686005, -0.08365035057067871, 0.03526357188820839, -0.06622657924890518, 0.001714368350803852, -0.22025054693222046, -0.20960266888141632, -0.09503388404846191, -0.016968021169304848, 0.08942228555679321, 0.17273622751235962, 0.1489126980304718, -0.053590551018714905, -0.0681324303150177, -0.14217516779899597, -0.055215783417224884, -0.14436209201812744, -0.04043937101960182, -0.03406353294849396, 0.07477206736803055, -0.058867499232292175, 0.006616024766117334, -0.028266653418540955, -0.07012522220611572, 0.12003062665462494, -0.10341471433639526, -0.08770491182804108, -0.2156636118888855, 0.024082491174340248, 0.01692478358745575, 0.008265542797744274, -0.1273970752954483, 0.03627029433846474, -0.18563972413539886, 0.0203765369951725, 0.0006387978792190552, 0.1053527444601059, 0.053397297859191895, 0.08025146275758743, -0.0055922409519553185, 0.06387297809123993, -0.001707213930785656, 0.03778419271111488, 0.04262164235115051, 0.02446732670068741, 0.12106004357337952, 0.09383012354373932, 0.10684158653020859, -0.056616269052028656, -0.005372161045670509, 0.17426833510398865, 0.011730335652828217, -0.11010469496250153, 0.07365114986896515, 0.15648116171360016, -1.0099054748025083e-07, -0.08079889416694641, 0.12880122661590576, -0.14233285188674927, 0.15745887160301208, -0.015443699434399605, -0.0786963552236557, 0.03468234837055206, -0.028890741989016533, -0.14029379189014435, 0.12224671244621277, 0.05615247040987015, 0.11799316853284836, -0.05195462703704834, -0.12439186871051788, 0.019687257707118988, -0.019342748448252678, -0.18731725215911865, 0.059585101902484894, -0.1429106742143631, 0.15804636478424072, 0.04793981462717056, -0.03245452046394348, 0.007259919308125973, -0.07172718644142151, -0.07155661284923553, -0.11485276371240616, 0.07100655883550644, -0.09163112193346024, -9.805198351386935e-05, -0.016447313129901886, 0.0060155391693115234, 0.018502790480852127, -0.08061115443706512, -0.20963625609874725, -0.14591702818870544, -0.02139419876039028, -0.0517975315451622, -0.018955521285533905, 0.1649397909641266, 0.11186258494853973, -0.0363381952047348, -0.21981343626976013, -0.047354575246572495, 0.048815127462148666, -0.11884276568889618, 0.009414982050657272, -0.12528453767299652, 0.10542812943458557, -0.10974830389022827, 0.15950031578540802, 0.03530821204185486, 0.13575780391693115, 0.16370561718940735, 0.004389106761664152, -0.04872266948223114, 0.08523064851760864, -0.008127372711896896, 0.10976791381835938, -0.05670647695660591, 0.01198522001504898, 0.1574026644229889, -0.10677939653396606, 0.026771260425448418, 0.038726430386304855], "changes": {"1wk": -18.23899842606254, "1mo": -34.276733638544094}}, {"text": "PREMIUM Climb Bio Names Douglas Williams Board Chair MT Newswires Mon, Nov 11, 2024, 3:27 PM Climb Bio Names Douglas Williams Board Chair PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLYM", "date": "2024-11-11T15:27:47", "sentiment": {"score": 0.029785260558128357, "confidence": 0.045073218643665314, "probabilities": {"positive": 0.045073218643665314, "negative": 0.015287958085536957, "neutral": 0.9396388530731201}}, "embedding": [-0.2366713285446167, -0.10079292953014374, -0.025158559903502464, 0.08059287816286087, 0.07535844296216965, 0.020751066505908966, -0.03770172595977783, 0.03537142649292946, -0.025512082502245903, 0.12615595757961273, -0.02252654917538166, -0.0604206807911396, -0.07963577657938004, 0.024942241609096527, -0.046383101493120193, 0.16913016140460968, 0.010964503511786461, 0.09146161377429962, 0.03355579823255539, 0.11261072009801865, -0.13506294786930084, -0.049974068999290466, -0.032694220542907715, 0.07874394953250885, -0.08543598651885986, -0.001188907423056662, -0.1556534767150879, 0.08327554166316986, -0.06589172780513763, -0.16725146770477295, -0.0255452748388052, -0.12401380389928818, 0.1611173301935196, 0.0015916447155177593, -0.052015773952007294, -0.018512122333049774, -0.13780750334262848, 0.013369928114116192, -0.10622690618038177, -0.09241137653589249, -0.027511391788721085, -0.1968267410993576, 0.04780341312289238, 0.0680842325091362, -0.09498480707406998, 0.08701028674840927, 0.0048282393254339695, -0.21171024441719055, 0.03933785855770111, 0.131581112742424, -0.17693819105625153, -0.24124473333358765, -0.0013510497519746423, -0.19884786009788513, -0.008323730900883675, 0.02569735236465931, -0.10238423943519592, -0.17535391449928284, -0.023106707260012627, -0.07969920337200165, 0.02265436388552189, -0.06239553168416023, -0.14346520602703094, 0.07402657717466354, -0.023247240111231804, 0.18353714048862457, -0.13385646045207977, 0.0013271524803712964, 0.0020479175727814436, -0.10843495279550552, 0.11132659018039703, 0.10509121417999268, 0.10891635715961456, -0.12008221447467804, 0.08895605057477951, 0.18055874109268188, 0.10748647153377533, 0.0805276557803154, 0.09916336089372635, -0.1314615160226822, -0.18117666244506836, -0.03750717267394066, -0.02748301438987255, -0.005594700109213591, 0.030073881149291992, 0.10280067473649979, -0.032861895859241486, -0.08321210741996765, -0.20874552428722382, -0.17628923058509827, 0.11786831170320511, -0.00821648444980383, 0.08704911172389984, 0.08656099438667297, -0.18250417709350586, 0.09437444806098938, -0.1579902321100235, -0.09938861429691315, -0.13918308913707733, 0.03954317420721054, -0.002256407868117094, 0.15233393013477325, -0.014030002057552338, 0.16151322424411774, -0.03553738072514534, -0.20611537992954254, -0.07206295430660248, 0.10202153027057648, 0.016250435262918472, 0.06726265698671341, 0.0521906353533268, 0.11978799104690552, 0.07036283612251282, 0.028456494212150574, -0.09043560177087784, 0.02213640697300434, -0.21509574353694916, -0.0038896873593330383, 0.14628489315509796, -0.021395843476057053, 0.010886715725064278, 0.09060411155223846, -0.006352144759148359, -0.005864199250936508, -0.08925385773181915, -0.042445942759513855, 0.0429559051990509, 1.450990994531073e-32, 0.09040404111146927, 0.0905882939696312, 0.09454261511564255, -0.08604652434587479, 0.13253772258758545, -0.00741418544203043, -0.047802090644836426, -0.16275644302368164, 0.0432419590651989, 0.1259368658065796, -0.14691533148288727, 0.11598741263151169, 0.1522177904844284, -0.0025703792925924063, -0.1305052638053894, -0.08471284806728363, 0.03942952677607536, -0.10451933741569519, -0.12442702054977417, 0.03333544358611107, 0.17129893600940704, 0.11798621714115143, -0.020578913390636444, 0.10418713092803955, 0.08029061555862427, 0.02774970792233944, 0.032302845269441605, -0.06517643481492996, -0.0058203148655593395, 0.1768469214439392, -0.17529024183750153, -0.12759467959403992, -0.11531790345907211, -0.05157211050391197, 0.19605402648448944, 0.0818040519952774, 0.18788586556911469, -0.1525055170059204, 0.014787387102842331, -0.07446829229593277, 0.01994912326335907, -0.07773125171661377, -0.0547030009329319, 0.00017790929996408522, -0.1254013180732727, 0.06692119687795639, 0.17160965502262115, 0.0326739139854908, 0.048622842878103256, -0.07506690174341202, -0.17283454537391663, 0.12953251600265503, 0.06978598237037659, -0.09255479276180267, -0.01868612878024578, -0.13003544509410858, -0.0463213287293911, 0.004678213968873024, 0.022251110523939133, 0.011018612422049046, 0.24460528790950775, 0.20228523015975952, 0.08927053213119507, 0.09031519293785095, -0.21800565719604492, -0.025363391265273094, -0.09416649490594864, -0.1539166122674942, -0.02586166374385357, -0.0028126428369432688, 0.1514042764902115, -0.020520662888884544, 0.13055482506752014, -0.037587035447359085, -0.205382838845253, 0.09309516847133636, -0.09786292910575867, -0.04647780954837799, 0.11167263984680176, 0.012945297174155712, 0.021709231659770012, 0.06379063427448273, 0.019460447132587433, -0.04522193595767021, 0.14792732894420624, -0.04618924856185913, -0.01818368025124073, -0.17500817775726318, -0.08829210698604584, 0.12964510917663574, -0.09574275463819504, 0.05368702486157417, 0.021533196792006493, 0.1564335823059082, -0.10140926390886307, -1.7668845301634234e-32, -0.04058818146586418, -0.1540849208831787, 0.22899770736694336, -0.12232670933008194, 0.15948350727558136, -0.12853313982486725, -0.09150189906358719, -0.012405059300363064, 0.1459873467683792, -0.023998120799660683, 0.06218484789133072, 0.12729433178901672, -0.05446499213576317, -0.06649371981620789, 0.2927011251449585, -0.012120634317398071, -0.08114046603441238, 0.0017606880282983184, -0.17836318910121918, 0.08887957036495209, 0.04188721254467964, 0.2479839324951172, -0.25865447521209717, 0.06170690432190895, 0.1987425535917282, -0.024827871471643448, 0.2258646935224533, 0.19775690138339996, 0.06215645372867584, -0.06439070403575897, -0.16253109276294708, 0.05493533983826637, -0.18839319050312042, 0.04571569710969925, -0.11760379374027252, 0.12927411496639252, 0.16897287964820862, -0.018811549991369247, -0.07561659812927246, -0.062043678015470505, 0.1946157068014145, -0.04872804135084152, 0.0748354122042656, 0.1016647219657898, 0.06200695037841797, -0.08302272111177444, -0.18657274544239044, 0.04205748066306114, -0.03204697370529175, -0.0573803149163723, -0.1409202516078949, -0.061308354139328, 0.0970875546336174, 0.059028588235378265, -0.012711442075669765, 0.08441170305013657, -0.05177075415849686, -0.03770480304956436, 0.11517547816038132, -0.03443156182765961, 0.04835396632552147, 0.09756344556808472, -0.1543618142604828, 0.04269373044371605, 0.029964102432131767, 0.04934873431921005, -0.0059019275940954685, -0.04645748808979988, -0.15305732190608978, -0.011887041851878166, -0.06776352226734161, -0.08385923504829407, -0.0954241082072258, -0.18000642955303192, -0.039118148386478424, 0.2789681851863861, -0.09305135160684586, 0.1402316391468048, -0.05496390908956528, -0.006487006787210703, 0.07343754172325134, -0.09726112335920334, 0.11427320539951324, 0.03267979249358177, 0.1202285960316658, 0.07259099185466766, 0.1108088418841362, -0.009186238050460815, -0.19833120703697205, -0.1686229705810547, 0.0139120789244771, -0.3213382363319397, -0.06567266583442688, 0.2006484866142273, -0.06903151422739029, -9.952819368663768e-08, 0.08013619482517242, 0.04958611726760864, -0.038392335176467896, -0.12834113836288452, 0.10409572720527649, 0.04976857826113701, 0.04024054855108261, -0.06227709352970123, -0.08366011083126068, 0.23020856082439423, 0.05883428081870079, 0.015295729041099548, 0.07605168968439102, 0.07579541206359863, 0.0692782774567604, 0.01253912877291441, -0.1343095302581787, 0.10044632107019424, -0.07485254108905792, -0.0719677209854126, 0.057771947234869, -0.07700968533754349, 0.30330511927604675, -0.036173947155475616, 0.0184775423258543, -0.0269455723464489, -0.024733562022447586, -0.0829375758767128, 0.09137659519910812, 0.06318274885416031, -0.04990855231881142, 0.09296692162752151, -0.03520955890417099, -0.014728047885000706, 0.2027994692325592, 0.16281342506408691, 0.05706373229622841, -0.020129548385739326, 0.028386255726218224, 0.0742044672369957, -0.004174163099378347, -0.12562833726406097, -0.006726263556629419, 0.1789613515138626, -0.010665548034012318, 0.03585631772875786, -0.11240460723638535, -0.001724225003272295, 0.11079908907413483, -0.17961429059505463, -0.03198447823524475, -0.14143525063991547, 0.07254894077777863, 0.09195230901241302, -0.05176278576254845, 0.20929010212421417, 0.05724438652396202, -0.004733078181743622, -0.08252707123756409, 0.0656476765871048, 0.22538278996944427, -0.1863107830286026, -0.12678314745426178, -0.05167669057846069], "changes": {"1wk": -25.862068155533947, "1mo": -24.137931844466053}}]